Deprenyl reduces inflammation during acute SIV infection

Highlights
- Deprenyl reduces peripheral and CNS inflammation in acute SIV infection
- Acute SIV infection alters monoamine levels in CNS
- Describes regional monoamine and metabolite levels in rhesus macaque brains
- Details levels of inflammatory analytes in healthy rhesus macaque peripheral blood
Deprenyl reduces inflammation during acute SIV infection

K.M. Emanuel, K. Runner, Z.D. Brodnik, B.M. Morsey, B.G. Lambert, H.S. Johnson, A. Acharya, S.N. Byrareddy, R.A. España, H.S. Fox, and P.J. Gaskill

SUMMARY

In the era of antiretroviral therapy, inflammation is a central factor in numerous HIV-associated comorbidities, such as cardiovascular disease, cognitive impairment, and neuropsychiatric disorders. This highlights the value of developing therapeutics that both reduce HIV-associated inflammation and treat associated comorbidities. Previous research on monoamine oxidase inhibitors (MAOIs) suggests this class of drugs has anti-inflammatory properties in addition to neuropsychiatric effects. Therefore, we examined the impact of deprenyl, an MAOI, on SIV-associated inflammation during acute SIV infection using the rhesus macaque model of HIV infection. Our results show deprenyl decreased both peripheral and CNS inflammation but had no effect on viral load in either the periphery or CNS. These data show that the MAOI deprenyl may have broad anti-inflammatory effects when given during the acute stage of SIV infection, suggesting more research into the anti-inflammatory effects of this drug could result in a beneficial adjuvant for antiretroviral therapy.

INTRODUCTION

The HIV pandemic remains a significant public health crisis, with more than 38 million people currently infected with HIV worldwide. While there is not yet a cure for HIV, the development and use of highly efficient antiretroviral therapy (ART) has dramatically reduced HIV-associated mortality, transforming HIV infection from a terminal diagnosis to a chronic condition (Deeks et al., 2013a). For individuals with access to early diagnosis and robust treatment options, lifespan can be similar to uninfected individuals (Marcus et al., 2016, 2020; May et al., 2014). Unfortunately, chronic HIV and long-term use of ART substantially increase the risk of comorbid diseases (d’Arminio Monforte et al., 2020; Ruzicka et al., 2015), meaning the quality of the added lifespan may be worse (Collins and Armstrong, 2020). These comorbidities include cardiovascular (Freiberg et al., 2013; Trant et al., 2007), liver (Perazzo and Luz, 2017) and kidney disease (Naicker et al., 2015), cognitive impairment and neuropsychiatric disorders such as depression, substance abuse, and anxiety (Cook et al., 2018; Milanini et al., 2017; Rubin and Maki, 2019; Saylor et al., 2016; Shiau et al., 2017), a number of non-AIDS defining cancers, and metabolic diseases such as diabetes (Hernandez-Romieu et al., 2017). Depending on the study, between 30%–90% of HIV-infected individuals present with at least one comorbidity, with a substantially greater disease burden in the aging population (Farahat et al., 2015), cognitive impairment and neuropsychiatric disorders such as depression, substance abuse, and anxiety (Cook et al., 2018; Milanini et al., 2017; Rubin and Maki, 2019; Saylor et al., 2016; Shiau et al., 2017), a number of non-AIDS defining cancers, and metabolic diseases such as diabetes (Hernandez-Romieu et al., 2017). Depending on the study, between 30%–90% of HIV-infected individuals present with at least one comorbidity, with a substantially greater disease burden in the aging population (Farahat et al., 2015), cognitive impairment and neuropsychiatric disorders such as depression, substance abuse, and anxiety (Cook et al., 2018; Milanini et al., 2017; Rubin and Maki, 2019; Saylor et al., 2016; Shiau et al., 2017), a number of non-AIDS defining cancers, and metabolic diseases such as diabetes (Hernandez-Romieu et al., 2017).
Regidor et al., 2011; Sereti et al., 2017; Shive et al., 2012; Temu et al., 2021; Wada et al., 2015; Yao et al., 2013). Many of these factors are produced by myeloid cells, such as monocytes and macrophages. These markers of myeloid activation are also sustained at elevated levels in infected individuals using ART (Jennes et al., 2004; Wada et al., 2015; Yao et al., 2013). Data on T cells are mixed as some studies show ART generally reduces T cell activation (Jennes et al., 2004; Korencak et al., 2019; Yao et al., 2013), while others suggest that T cells may remain in a more active state (Adland et al., 2018; Warren et al., 2019) during ART. This shows the importance of developing supplemental therapeutics that suppresses HIV-associated inflammation in the context of ART to reduce the increasing health and financial costs associated with non-AIDS-related diseases.

One method by which this concern could be addressed is through the repurposing of existing drugs that have shown anti-inflammatory activity but are not currently used for that purpose. Monoamine oxidase inhibitors (MAOIs), such as deprenyl (also called selegiline) or rasagiline, are well studied therapeutics that is widely used to treat Parkinson disease and major depressive disorder (Finberg and Rabey, 2016). Many studies have also shown that these drugs can regulate inflammation and the production of reactive oxygen species (ROS) (Bekesi et al., 2012; Bielecka et al., 2010; Lieb, 1983; Morsali et al., 2013; Nagy et al., 2018; Sanchez-Rodriguez et al., 2020; Tsao et al., 2014). A clinical trial testing the impact of the selegiline transdermal system on cognitive impairment (ACTG5090) in 128 HIV-infected individuals on stable ART found that this system is safe and well-tolerated by HIV-infected individuals with cognitive impairment (Evans et al., 2007; Schifitto et al., 2007). Changes in inflammatory biomarkers were not examined in this trial. Still, the safety data from this study, combined with the established anti-inflammatory effects of deprenyl suggest untapped potential as an anti-inflammatory therapy during HIV infection. Further, deprenyl is an effective antidepressant, providing the possibility to simultaneously treat multiple comorbidities, a welcome effect given the high prevalence of comorbid depression in PLWH (Bhatia and Munjal, 2014; Hobkirk et al., 2015; Pinheiro et al., 2016; Wang et al., 2018).

To examine the impact of deprenyl on HIV-associated inflammation, rhesus macaques were treated with deprenyl prior to and during acute SIV infection, and the changes in infection, plasma inflammatory biomarkers, and gene expression were analyzed. While deprenyl treatment did not affect peripheral or CNS viral load, it did reduce expression of inflammatory biomarkers in the plasma. It also resulted in broad decreases in inflammatory gene expression in different regions of the CNS. To assess the efficacy of deprenyl treatment, brain regions were examined for changes in dopamine levels. Treatment with deprenyl increased dopamine and decreased DOPAC in the dopamine-rich caudate and did not affect dopamine levels in other regions with less dopamine innervation such as the hippocampus and cerebellum, indicating that the drug was acting as expected. Overall, these data confirm the safety profile for deprenyl during HIV/SIV infection and suggest that deprenyl and potentially other MAOIs have substantial untapped potential as candidates for repurposing as anti-inflammatory agents during HIV infection.

RESULTS
Deprenyl does not alter SIV replication
To assess the impact of deprenyl on the development of inflammation during acute infection, rhesus macaques were treated with deprenyl prior to and during acute SIV infection. Starting one week prior to SIV infection, baseline immune measurements were taken and animals were split into two groups of eight and given daily intramuscular injections of either vehicle (saline) or deprenyl (2 mg/kg), as has been used in previous studies (Czub et al., 2001, 2004). After one week, immune measurements were repeated; four animals from each group were infected with SIVmac251, while the other four were mock-infected using saline. Daily deprenyl injections continued for two weeks following infection, with blood and CSF draws and immune measurements performed on days 7 and 14 post infection. All animals were sacrificed at 14 days post infection providing samples from four animals in each experimental group: uninfected + saline, uninfected + deprenyl, SIV + saline, and SIV + deprenyl. This early timepoint was chosen because two weeks post infection is a reproducible time in terms of viremia and levels of virus in the brain and is when inflammatory molecule production peaks in the periphery and CNS, providing the most consistency between animals (Gopalakrishnan et al., 2021; Parker et al., 2001; Roberts et al., 2004).

To examine the impact of deprenyl on early SIV infection, we first examined the impact on viral replication. Viral load (copies of SIV RNA/mL) was quantified in the plasma and CSF in the SIV + saline and SIV + deprenyl groups at 7 and 14 days post inoculation (dpi) using qRT-PCR (Figures 1A and 1B). Several brain
regions (frontal cortex, hippocampus, caudate, and corpus callosum) and the spleen were also analyzed for viral replication by assessing the copies of SIV RNA per µg of RNA at 14 dpi (Figure 1C). There was no significant difference between viral load in SIV + saline animals (blue) and SIV + deprenyl animals (red) in either biofluid or any tissue region examined. Microglial activation typifies active brain infection by HIV and SIV, and indeed a significant effect of infection was found (Figures 2A–2C). SIV-infected cells, consistent with perivascular macrophages, could be identified by in situ hybridization (Figure 2D); their relative rarity precluded quantification.

Deprenyl reduces peripheral immune activity and inflammation

To assess the effect of deprenyl on peripheral inflammation, plasma immune populations were examined using flow cytometry and secreted immune factors were evaluated using multianalyte profiling. Immune cell populations were analyzed in plasma prior to SIV inoculation (day 0) and at 7 and 14 dpi (Figures 3A–3D). While there were changes in the immune populations between treatment groups, the small number of animals used likely limited the statistical significance of these findings. In the saline-treated animals, CD4⁺ T cells decreased, and CD8⁺ T cells increased, at 14 dpi. Animals treated with deprenyl showed decreases in CD4⁺ T cells; however, CD8⁺ T cells showed little change with infection. Relative to animals treated with saline, deprenyl-treated animals had significantly lower numbers of CD8⁺ T cells in the blood at 7 dpi. In addition, the proportion of proinflammatory monocytes (CD14⁺ CD16⁺) within the monocyte population was decreased in deprenyl-treated animals at 14 dpi. To measure the effect of deprenyl on secreted inflammatory factors, plasma from SIV + saline and SIV + deprenyl groups collected at day 0, 7, and 14 dpi was analyzed for levels of inflammatory factors found in the plasma (Table 1). Deprenyl significantly decreased the concentrations of ten analytes on days 7 and/or 14; brain-derived neurotrophic factor (BDNF), C-reactive protein (CRP), insulin, interleukin-8 (IL-8, CXCL8), interleukin-16 (IL-16), plasminogen activator inhibitor-1 (PAI-1), serum amyloid P-component (SAP), regulated on activation, normal T cell expressed and secreted (RANTES, CCL5), thrombospondin-1, and tumor necrosis factor
receptor 2 (TNFR2). In contrast, deprenyl increased IL-6 levels at day 7. An additional 35 analytes were unchanged with deprenyl treatment. Analytes that were significantly decreased or increased (Figure 4A), as well as examples of factors not altered by deprenyl treatment (Figure 4B) are shown. The concentration and statistical comparisons of all detected analytes at 7 and 14 dpi in both SIV + saline and SIV + deprenyl groups are shown in Table 1. This table also shows the concentrations of these analytes detected in healthy rhesus macaques, none altered by deprenyl in uninfected macaques.

Deprenyl decreases brain inflammatory gene expression

To assess the impact of deprenyl on the development of SIV-associated inflammation, RNA isolated from the frontal gray matter, caudate, hippocampus, and spleen at necropsy were analyzed for changes in inflammatory gene expression by using the NanoString nCounter Non-human Primate Inflammation panel (Table S2). In all three regions of the brain, SIV infection led to significant (>2-fold, corrected p-value <0.05) increase in numerous inflammatory genes (Figure 5A upper row). The spleen had both up- and downregulated genes (Figure 5A upper row). Treatment with deprenyl in SIV-infected animals led to significant changes in many of these genes in the caudate and frontal cortex, with no significant differences found in the hippocampus or spleen. Examples of genes significantly upregulated by SIV, and significantly downregulated in the presence of deprenyl, in the caudate and frontal cortex, are shown in Figure 5B. These are notable for chemokines (CCL2, CXCL10, and CXCL11), adhesion molecules (ICAM1, ICAM2, PECAM1, and VCAM1), interferon-inducible genes (GBP1, IRF1, and TAP1) including the immunoproteasome (PSMB8, PSMB9, and PSMB10), and antiviral genes (OAS2 and BST2). The full list of genes significantly (>2-fold, corrected p-value <0.05) altered by deprenyl in caudate and frontal cortex of SIV-infected animals is found in Table S3. None of these effects were seen in uninfected animals treated with deprenyl (Figure 5A, bottom row), suggesting that the anti-inflammatory activity of this drug may be specifically in response to SIV-associated neuroinflammation.

Deprenyl and SIV alter monoamine metabolism

To verify that deprenyl was biologically active and functioning as expected under the conditions of this study, dopamine metabolism was assessed across different brain regions from all animals in the saline, deprenyl, SIV + saline, and SIV + deprenyl groups. These studies also enabled examination of alterations in regional brain biogenic amine and metabolite levels during SIV infection, something that has not been previously defined. Mood and anxiety disorders such as major depressive disorder and generalized anxiety disorder are highly comorbid with HIV (Beer et al., 2019; Camara et al., 2020; Nanni et al., 2015; Remien et al., 2019; Wang et al., 2018). As dysregulation of biogenic amine signaling has been implicated in the etiology of these disorders (Dunlop and Nemeroff, 2007; Lin et al., 2014; Mann, 2013; Mann and Currier, 2007), defining changes in biogenic amine levels may suggest mechanisms by which HIV infection could drive comorbid neuropsychiatric conditions.

As deprenyl is a monoamine oxidase inhibitor, it should prevent monoamine oxidase from metabolizing dopamine into its metabolite 3,4-dihydroxyphenylaceticacid (DOPAC). Sections of the caudate, putamen, substantia nigra, hippocampus, cerebellum, and frontal cortex were isolated from each animal, rapidly dissected in ice-cold HeGA to protect monoamines from oxidation, then processed and stored at
Two samples were examined from each brain section in each animal, except for the substantia nigra, which was only large enough to generate samples from each animal. Samples were analyzed for concentration of the dopamine metabolite DOPAC, and for concentrations of dopamine and homovanillic acid (HVA), a downstream dopamine metabolite produced by catechol-O-methyltransferase mediated metabolism of DOPAC.

In accordance with its activity as an MAO-I, deprenyl treatment significantly decreased DOPAC levels in the caudate, putamen, and substantia nigra (Figure 6A). This indicates deprenyl was biologically active, blocking the degradation of dopamine into DOPAC in dopamine-rich regions. In addition, we found that deprenyl treatment produced an increase in caudate dopamine levels but had no impact on dopamine levels in other brain regions (Figure 6B). Deprenyl treatment also did not affect levels of HVA, 5-HT, or 5-HIAA across any brain region tested (Figures S1, S2, and S3). As expected, dopamine concentrations were variable between brain regions, with the highest levels in striatal regions (caudate and putamen) and the lowest levels in the cerebellum. However, it was surprising to see that SIV infection increased frontal cortex DA, DOPAC, HVA, and 5-HT (Figures 6A, 6B, S1, and S2), increased caudate DA (Figure 6B), and increased substantia nigra 5-HT (Figure 6B). These results indicate that SIV infection alone results in gross disruptions to biogenic amine synthesis, signaling, and/or metabolism in the frontal cortex as well as less pronounced disruptions to caudate DA and substantia nigra 5-HT.

We did not observe any significant interaction between SIV infection and deprenyl treatment for dopamine, DOPAC, or HVA (Figures 6A, 6B, and S1). However, the SIV-induced increase in 5-HT levels in the frontal cortex was normalized by deprenyl treatment (Figure S2). In addition, deprenyl-induced elevations in putamen and frontal cortex 5-HIAA levels were absent in SIV-infected subjects (Figure S3). This suggests
Table 1. Values of analytes detected by Human v2.0 Multianalyte profile immunoassay in SIV-infected saline versus deprenyl-treated macaques

| Analyte (units)                     | Abbr.    | Range in healthy animals | Day 7 SIV + Saline (ng/mL) | Day 7 SIV + deprenyl (ng/mL) | Day 7 Saline versus deprenyl | Day 14 SIV + Saline (ng/mL) | Day 14 SIV + deprenyl (ng/mL) | Day 14 Saline versus deprenyl |
|-------------------------------------|----------|--------------------------|----------------------------|-------------------------------|-----------------------------|-----------------------------|-------------------------------|-------------------------------|
| Adiponectin (µg/mL)                 |          |                          |                            |                               |                             |                             |                               |                               |
| Alpha-1-Antitrypsin (mg/mL)         | AAT      | 0.094 - 0.26             | 0.138 ± 0.012              | 0.218 ± 0.022                 | 0.22 ± 0.028                | 0.28 ± 0.022                 | 0.22 ± 0.028                  | 0.28 ± 0.022                  |
| Alpha-2-Macroglobulin (mg/mL)       | A2Macro  | 0.82 - 2.1               | 0.99 ± 0.14                | 1.02 ± 0.12                   | 0.7210                      | 1.23 ± 0.15                  | 1.3 ± 0.082                   | 0.6580                        |
| Alpha-Fetoprotein (ng/mL)           | AFP      | 1.14 ± 0.56              | 1.93 ± 1.85                | 3.18 ± 1.58                   | 0.6350                      | 4.45 ± 2.81                  | 9.25 ± 6.204                  | 0.1626                        |
| Apolipoprotein(a) (µg/mL)           | Lp(a)    | 77.1130                  | 232.5 ± 92.13              | 219.75 ± 100.06               | 0.9212                      | 467.25 ± 176.10              | 402.25 ± 279.22              | 0.8525                        |
| Apolipoprotein A-I (ng/mL)          | Apo A-I  | 0.58-2.8                 | 1.60 ± 0.29                | 1.63 ± 0.50                   | 0.9544                      | 1.18 ± 0.79                  | 2.10 ± 0.71                   | 0.1007                        |
| Apolipoprotein A-II (ng/mL)         | Apo A-II | 198.495                  | 522.00 ± 48.67             | 397.00 ± 37.90                | 0.1903                      | 626.25 ± 169.56              | 528.00 ± 82.69                | 0.1903                        |
| Apolipoprotein C-I (ng/mL)          | Apo C-I  | 103.273                  | 171.25 ± 24.45             | 169.25 ± 29.05                | 0.9635                      | 212.25 ± 87.39               | 279.75 ± 74.50                | 0.2612                        |
| Apolipoprotein C-III (µg/mL)        | Apo C-III| UN-185                   | 85.33 ± 18.01              | 83.00 ± 0.00                  | 0.4246                      | 148.50 ± 63.75               | 203.25 ± 59.06                | 0.2520                        |
| Brain-Derived Neurotrophic Factor (ng/mL) | BDNF | 0.595 ± 0.302             | 0.113 ± 0.056              | 0.0262                        | 0.70 ± 0.06                  | 0.17 ± 0.10                  | 0.1703                        |
| C-Reactive Protein (µg/mL)          | CRP      | UN-0.95                  | 0.051 ± 0.00               | 0.050 ± 0.007                 | 0.8056                      | 0.285 ± 0.199                | 0.0370 ± 0.000                | 0.0145                        |
| Complement C3 (mg/mL)               | C3       | 0.33-1.2                 | 0.365 ± 0.051              | 0.385 ± 0.031                 | 0.6387                      | 0.703 ± 0.055                | 0.6250 ± 0.085                | 0.1657                        |
| Factor VII (ng/mL)                  | FRTN     | 8.5-165                  | 25.5 ± 11.9                | 45.0 ± 16.1                   | 0.4775                      | 154.50 ± 34.55               | 136.50 ± 27.40                | 0.4775                        |
| Ferritin (ng/mL)                    | UN-186   | 817.5 ± 647.5            | 960.0 ± 717.7              | 0.9187                        | 291.8 ± 199.1               | 153.0 ± 53.2                 | 0.9187                        |
| Fibrinogen (mg/mL)                  | UN-1.6   | 0.061-0.44               | 0.102 ± 0.020              | 0.131 ± 0.053                 | 0.4923                      | 0.140 ± 0.016                | 0.125 ± 0.026                 | 0.5817                        |
| Growth Hormone (ng/mL)              | GH       | 0.286                    | 26.88 ± 21.60              | 15.28 ± 7.37                  | 0.4673                      | 2.90 ± 2.97                  | 12.33 ± 7.34                  | 0.4673                        |
| Haptoglobin (mg/mL)                 | UN-199   | 0.368 ± 0.271            | 0.560 ± 0.096              | 0.6840                        | 0.95 ± 0.509                 | 0.743 ± 0.244                | 0.6840                        |
| Insulin (µU/mL)                     | UN-24    | 11.00 ± 2.55             | 3.93 ± 1.91                | 0.0140                        | 4.85 ± 0.55                  | 4.53 ± 3.77                  | 0.7077                        |
| Interleukin-1 receptor antagonist (pg/mL) | IL-1ra | 1577.5 ± 273.6           | 1977.5 ± 366.8             | 0.1308                        | 343.0 ± 114.2               | 277.5 ± 124.8                | 0.7479                        |
| Interleukin-6 (pg/mL)               | IL-6     | UN-19                    | 6.03 ± 1.38                | 29.75 ± 16.24                 | 0.0081                      | 4.40 ± 0.90                  | 4.40 ± 0.00                   | 0.9185                        |
| Interleukin-8 (pg/mL)               | CXCL8, IL-8 | 26-1160               | 272.75 ± 172.62            | 202.50 ± 72.24                | 0.8709                      | 184.25 ± 135.32              | 103.75 ± 19.51                | 0.0181                        |
| Interleukin-12 Subunit p40 (ng/mL)   | IL-12p40 | UN-0.53                  | 0.30 ± 0.00                | 0.22 ± 0.00                   | 0.5316                      | 0.34 ± 0.10                  | 0.28 ± 0.00                   | 0.5316                        |
| Interleukin-16 (pg/mL)              | IL-16    | UN-217                   | 77.50 ± 3.64               | 82.00 ± 4.42                  | 0.7347                      | 90.50 ± 27.80                | 52.25 ± 14.29                 | 0.0242                        |
| Interleukin-18 (pg/mL)              | IL-18    | UN-179                   | 470.00 ± 165.83            | 915.25 ± 519.57               | 0.1750                      | 771.00 ± 122.09              | 715.00 ± 204.14               | 0.8216                        |
| Macrophage-Derived Chemokine (pg/mL) | MDC | 32-425                   | 260.25 ± 94.23             | 174.25 ± 28.14                | 0.3126                      | 399.75 ± 153.23              | 250.75 ± 82.41                | 0.1770                        |
| Macrophage Inflammatory Protein-1 beta (pg/mL) | MIP-1β, CCL4 | 178-2150               | 690.50 ± 120.88            | 1266.25 ± 1184.30             | 0.6981                      | 703.00 ± 109.86              | 1172.5 ± 1188.28              | 0.6981                        |
| Matrix Metalloproteinase-2 (ng/mL)   | MMP-2    | 2680-5100                | 4095.0 ± 778.38            | 4847.5 ± 1177.9               | 0.5982                      | 5090.0 ± 354.9               | 5285.0 ± 337.9                | 0.8118                        |

(Continued on next page)
| Analyte (units)                              | Abbr.     | Range in healthy animals | Day 7 SIV + Saline | Day 7 SIV + deprenyl | Day 7 Saline versus deprenyl | Day 14 SIV + Saline | Day 14 SIV + deprenyl | Day 14 Saline versus deprenyl |
|--------------------------------------------|-----------|--------------------------|--------------------|----------------------|-------------------------------|---------------------|---------------------|-------------------------------|
| Matrix Metalloproteinase-3 (ng/mL)         | MMP-3     | 0.8-3.2                  | 0.820 ± 0.186      | 1.055 ± 0.102        | p = 0.4452                    | 1.675 ± 0.259       | 2.30 ± 0.648         | p = 0.1119                      |
| Matrix Metalloproteinase-9 (ng/mL)         | MMP-9     | UN-349                   | 46.33 ± 9.53       | 41.33 ± 3.77         | p = 0.7166                    | 68.50 ± 8.29        | 60.50 ± 14.84        | p = 0.6900                      |
| Monocyte Chemoattract Protein 1 (pg/mL)    | MCP-1, CCL2| UN-380                   | 1084.25 ± 219.04   | 918.75 ± 276.21      | p = 0.5085                    | 341.75 ± 112.70     | 202.00 ± 49.56       | p = 0.5085                      |
| Myeloperoxidase (ng/mL)                    | MPO       | 28-2400                  | 442.75 ± 244.65    | 1211.0 ± 676.5       | p = 0.0625                    | 413.5 ± 253.3       | 269.5 ± 135.8        | p = 0.6570                      |
| Myoglobin (ng/mL)                          | NSE       | UN-1                     | 0.557 ± 0.113      | 0.460 ± 0.228        | p = 0.8814                    | 0.568 ± 0.284       | 0.388 ± 0.084        | p = 0.5622                      |
| Plasminogen Activator Inhibitor 1 (ng/mL)  | PAI-1     | 3.2-128                  | 49.50 ± 10.45      | 22.75 ± 10.06        | p = 0.0084                    | 16.58 ± 11.45       | 9.80 ± 2.01          | p = 0.3895                      |
| Serum Amyloid                              | SAP       | 0.69-6.9                 | 2.90 ± 0.35        | 3.40 ± 0.78          | p = 0.4190                    | 4.60 ± 0.99         | 3.03 ± 0.66          | p = 0.0430                      |
| Serum Amyloid P-Component (ug/mL)          | SCF       | UN-474                   | 233.67 ± 26.40     | 300.50 ± 85.50       | p = 0.9844                    | 415.00 ± 150.77     | 322.75 ± 67.98       | p = 0.5278                      |
| T-Cell-Specific Protein RANTES (ng/mL)     | RANTES, CCL5| 0.2-16                   | 4.28 ± 1.73        | 0.90 ± 0.46          | p = 0.0154                    | 4.69 ± 4.40         | 1.38 ± 0.52          | p = 0.0154                      |
| Thrombospondin-1 (ng/mL)                   | TIMP-1    | 32-151                   | 96.75 ± 8.84       | 83.50 ± 9.39         | p = 0.1793                    | 88.50 ± 15.11       | 66.25 ± 11.10        | p = 0.0666                      |
| Tissue Inhibitor of Metalloproteinas 1 (ng/mL) | UN-474 | 209-389                  | 555.75 ± 103.92    | 669.50 ± 67.45       | p = 0.1521                    | 576.50 ± 67.77      | 495.25 ± 34.07       | p = 0.1958                      |
| Transthyretin (mg/dL)                      | TTR       | UN-13                    | ND                  | 5.4 ± 0.00           | ND                            | 4.85 ± 0.75         | 7.05 ± 2.50          | p = 0.1683                      |
| Tumor necrosis factor receptor 2 (ng/mL)   | TNFR2     | UN-4.9                   | 7.53 ± 1.93        | 8.40 ± 1.88          | p = 0.5647                    | 11.90 ± 2.10        | 7.65 ± 1.19          | p = 0.0277                      |
| Vascular Cell Adhesion Molecule-1 (ng/mL)  | VCAM-1    | 209-389                  | 555.75 ± 103.92    | 669.50 ± 67.45       | p = 0.1521                    | 576.50 ± 67.77      | 495.25 ± 34.07       | p = 0.1958                      |
| Vascular Endothelial Growth Factor (pg/mL) | VEGF      | UN-112                   | ND                  | 60.00 ± 0.00         | ND                            | 60.00 ± 16.97       | 54.00 ± 0.00         | p = 0.2136                      |
| Vitamin D-Binding Protein (ug/mL)          | VDBP      | UN-300                   | 22.00 ± 4.00       | 24.25 ± 6.02         | p = 0.2624                    | 39.75 ± 4.09        | 45.75 ± 8.23         | p = 0.2743                      |
| von Willebrand Factor (ug/mL)              | vWF       | 87-429                   | 360.25 ± 59.60     | 328.50 ± 89.30       | p = 0.5729                    | 205.25 ± 59.69      | 153.25 ± 42.48       | p = 0.5729                      |

Values in bold were significantly different between SIV + saline and SIV + deprenyl conditions. ND; not detected, UN; undetectable.
DISCUSSION

Although efficacious antiretroviral therapy (ART) has transformed HIV infection into a chronic condition (Deeks et al., 2013a), PLWH can still develop HIV-related or other comorbid diseases. These comorbidities vary, but many are associated with chronic inflammation, which is prevalent in ART-treated PLWH (Deeks et al., 2013b; Negin et al., 2012; Pelchen-Matthews et al., 2018; Peterson and Baker, 2019; Yang et al., 2019). One frequent comorbidity is depression (Bhatia and Munjal, 2014; Hobkirk et al., 2015; Pinheiro et al., 2016; Wang et al., 2018), which is increasingly associated with peripheral inflammation (Miller and Raison, 2016). Therefore, therapeutics that simultaneously ameliorates inflammation and depression would be valuable adjuvants for ART. With this in mind, we examined the impact of the antidepressant deprenyl on SIV infection and SIV-associated inflammation during a reproducible infection phase, acute SIV infection. We found that deprenyl was remarkably potent in decreasing peripheral (in the blood plasma) inflammatory factors.

Figure 4. Plasma collected from all SIV-infected animals (4 SIV + saline and 4 SIV + deprenyl) was analyzed for levels of 85 distinct inflammatory factors using a Human v2.0 Multianalyte profile immunoassay (Myriad-RBM).

Relative to saline-treated animals, plasma from deprenyl-treated animals showed significantly decreased concentrations of ten analytes on days 7 and/or 14 [A, multiple unpaired t-tests corrected for multiple comparisons using the Holm-Sidak method; BDNF day 7, 88.5% decrease, \( t = 2.905, \* p = 0.0262 \); CRP day 14, 92.3% decrease, \( t = 3.227, \* p = 0.0145 \); insulin day 7, 64.3% decrease, \( t = 3.244, \* p = 0.0140 \); IL-8 days 14, 88.5% decrease, \( t = 3.106, \* p = 0.0181 \); IL-6 days 7, 39.8% decrease, \( t = 3.540, \* p = 0.0081 \); IL-16 days 14, 42.3% decrease, \( t = 3.949, \* p = 0.0242 \); IL-1 day 7, 54% decrease, \( t = 3.525, \* * p = 0.0084 \); IL-16 day 14, 34.2% decrease, \( t = 2.636, \* p = 0.0430 \); CCL5 days 7 and 14, 79.7% decrease, \( t = 3.194, \* p = 0.0154 \); day 14, 75.2% decrease, \( t = 3.042, \* p = 0.0154 \); thrombospondin-1 day 7, 79.5% decrease, \( t = 2.887, \* p = 0.0271 \); TNFR2 day 14, 35.7% decrease, \( t = 2.887, \* p = 0.0277 \)]. Examples of factors not altered by deprenyl are shown (B). A total of 11 analytes were changed by deprenyl treatment in the SIV-infected animals, 35 analytes were unchanged, while another 39 analytes were not detected.

that deprenyl treatment similarly impacts dopamine indices in control and SIV-infected subjects, but may differentially impact serotonin synthesis, signaling, and/or metabolism depending on infection status.
Deprenyl, also known as L-deprenyl or selegiline, was developed as an antidepressant in the 1960s, acting as a potent inhibitor of monoamine oxidase-B (MAO-B) (Knoll et al., 1965), the primary form of monoamine oxidase found in the human CNS. Deprenyl can also inhibit MAO-A in the CNS when delivered in formulations that bypass first-pass metabolism in the liver (Fowler et al., 2015), which would be the case in our experiment as it was injected, not given orally. Some data show monoamine oxidase inhibitors (MAOI) have pleiotropic effects that are not well defined (Kitani et al., 2001; Szoko et al., 2018) and may be unrelated to monoamine oxidase inhibition (Koutsilieri et al., 1996; Kragten et al., 1998; Lieb, 1983; Nagatsu and Sawada, 2006; Ryu et al., 2018; Tabakman et al., 2004; Tatton et al., 1994). In animal models, these overlapping effects include regulation of inflammation and reactive oxygen species (ROS) (Bekesi et al., 2012; Bielecka et al., 2010; Morsali et al., 2013; Nagy et al., 2018; Tsao et al., 2014), alterations in gene expression (Tatton and Chalmers-Redman, 1996; Tatton et al., 1996), increasing longevity (Kitani et al., 1994, 1998; Knoll and Miklya, 2016), and promoting neurite outgrowth and neuronal survival (Abdanipour et al., 2018; Ebadi et al., 2002; Koutsilieri et al., 1994; Kragten et al., 1998; Morsali et al., 2013; Tazik et al., 2009). In the rodent heart, inhibiting monoamine oxidase reduces inflammation and endothelial dysfunction in the aorta (Ratiu et al., 2018; Sturza et al., 2013), decreasing ROS and preventing mitochondrial dysfunction and ER stress in diabetic cardiomyopathy (Deshwal et al., 2018). Also in rodents, inhibiting monoamine oxidase reduced LPS-mediated TNF-α and ROS production in a model of chronic wound formation (Ekuini et al., 2009). In rodent glia, the MAO inhibitor moclobemide reduced LPS-mediated increases in IL-1β, TNF-α, and NF-κB activity (Bielecka et al., 2010). The MAOI rasagiline decreased NLRP3 activation and IL-1β secretion in mouse bone-marrow-derived macrophages by inhibiting production of mitochondrial ROS and subsequent NF-κB activation (Sanchez-Rodriguez et al., 2020).

There are relatively few studies examining MAOI in humans or human cell models of inflammatory disease. Moclobemide reduces LPS-induced increases in TNF-α and IL-8 in human blood (Lin et al., 2000) and deprenyl blocks increases in IL-8, ROS production, and NF-κB activation in human airway epithelial cells exposed to cigarette smoke medium (Cui et al., 2017). In a series of case reports, MAOI were shown to reduce the symptoms of rheumatoid arthritis (Lieb, 1983), and deprenyl acts through an MAO-independent mechanism to reduce mitochondrial respiration and ROS production in human myeloid leukemia cells (Ryu et al., 2018). In the context of HIV, the impact of treatment with transdermal selegiline (i.e. deprenyl) on cognitive function was examined in a clinical trial (ACTG5090), although this trial did not examine
the impact on inflammation. In this trial, a primarily male, majority-white cohort of 128 HIV-infected, ART-treated individuals with cognitive impairment showed no cognitive improvement after 24 weeks of transdermal deprenyl treatment, although modest improvements in several cognitive domains were found at 24 and 48 weeks (Evans et al., 2007; Schifitto et al., 2007). Analyses of a subgroup using proton magnetic resonance spectroscopy showed deprenyl did not decrease oxidative stress or ameliorate brain metabolite changes, nor abnormalities associated with HIV infection (Schifitto et al., 2009). Notably, the trial showed no effect of deprenyl on viral load after 24–48 weeks, and inflammatory biomarkers were not examined in this trial, so the impact of deprenyl on inflammation is not clear. Our findings corroborate a lack of effect on viral replication, showing that deprenyl had no effect on SIV load in the plasma, CSF, brain, or spleen. However, deprenyl did show broad anti-inflammatory effects in the CNS and periphery at 1–2 weeks post infection. Notably, our study shows that deprenyl did not suppress inflammatory biomarkers or gene expression in mock-infected macaques, suggesting the anti-inflammatory impact may be specifically in response to the inflammation induced by SIV infection.

**Figure 6. Brain sections were analyzed for monoamines and metabolites by HPLC**

(A) Two samples from each monkey were analyzed from the caudate, putamen, frontal cortex, hippocampus, and cerebellum of all SIV-infected animals (4 SIV + saline and 4 SIV + deprenyl) and averaged, while a single sample was examined from each substantia nigra. Each brain region was analyzed for the concentrations of dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC, A) and dopamine.

(B) Treatment with deprenyl significantly decreased DOPAC concentrations in the caudate, putamen, and substantia nigra, while SIV, but not deprenyl, significantly increased DOPAC in the frontal cortex [A, 2-way ANOVA, SIV x deprenyl; (caudate; SIV; F (1, 11) = 0.0205, p = 0.889; deprenyl, F (1, 11) = 51.97, ***p < 0.0001); (putamen; SIV, F (1, 11) = 1.979, p = 0.1871; deprenyl, F (1, 11) = 33.70, ***p = 0.0001); (substantia nigra; SIV, F (1, 11) = 0.5178, p = 0.4883; deprenyl, F (1, 11) = 7.859, *p = 0.0187); (frontal cortex; SIV, F (1, 11) = 16.05, ** = 0.0025; deprenyl, F (1, 11) = 6713, p = 0.8008)]. Assessment of dopamine concentrations showed that both SIV and deprenyl increased dopamine in the caudate, although there was no interaction. Additionally, SIV, but not deprenyl, significantly increased dopamine in the frontal cortex [B, 2-way ANOVA, SIV x deprenyl; (caudate; SIV, F (1, 10) = 6.711, *p = 0.0283; deprenyl, F (1, 10) = 6.711, *p = 0.0269); (frontal cortex, SIV, F (1, 10) = 5.360, *p = 0.0431; deprenyl, F (1, 10) = 2.168, p = 0.1717)].
In the periphery, deprenyl treatment lowered the plasma level of many inflammatory biomarkers that were increased in response to SIV infection. For example, CRP was increased significantly in the saline-treated SIV-infected animals at day 14 but was not elevated in the infected animals administered deprenyl. Similarly, the SIV-induced elevation of TNFR2 was ablated by deprenyl. Effects on immune mediators were also present, as exemplified by the chemokines IL-8 and CCL5. Deprenyl also affected peripheral immune cells, with reductions in the CD8⁺ T cell and inflammatory monocyte populations.

In the CNS, deprenyl mediated substantial reductions in SIV-infected inflammatory gene expression in the frontal gray matter and caudate. This is exemplified in the changes in the gene expression of the chemokines CCL2, CXCL10, CXCL11, and CCL1 in the brain. For CCL2, which drives monocyte transmigration into the CNS and is important to the development of neuroHIV, SIV infection increased expression in both the caudate and frontal cortex, and deprenyl treatment decreased CCL2 expression in both regions in the infected animals. Similar findings occurred for the T cell chemoattractants CXCL10 and CXCL11. Interestingly, while SIV infection significantly increased CXCL10 and CXCL11 in the hippocampus, it did not increase CCL2 in this area, suggesting regionally specific responses to infection.

Further, deprenyl did not significantly decrease CXCL10 or CXCL11 (or other increased genes) in the hippocampus as it does in the frontal cortex or caudate, also indicating regional-specific responses in the brain to deprenyl. In contrast to CCL2, CXCL10, and CXCL11, CCL1, a chemoattractant for monocytes and T lymphocytes, was one of the two genes that was significantly downregulated in the frontal cortex of SIV-infected animals. Interestingly, deprenyl significantly upregulated CCL1 expression in that brain region in infected animals. These data suggest that the anti-inflammatory effects of deprenyl are not inherent to this drug but are based on the environment and only occur in response to specific inflammatory changes. This also suggests that the anti-inflammatory impact of MAOIs may be more challenging to evaluate, as the effects are situational.

The mechanism(s) by which deprenyl suppresses inflammation, particularly peripheral inflammation, is not well understood. As noted above, deprenyl and other MAO-I have broad anti-inflammatory effects in both rodent and human systems. These effects may be unrelated to their impact on monoamine oxidases (MAOs), but they could also be associated with inhibition of MAO activity in various cell types. The peripheral bioactivity of deprenyl is not defined, but both types of MAO are expressed in the periphery, across many organ systems and in several types of immune cells, although the level of expression and activity is considerably less than in the CNS (Billett, 2004; Rodriguez et al., 2001; Sivasubramaniam et al., 2003). The effects of deprenyl on inflammation may also vary between the CNS and periphery, and among peripheral organs, depending on the cell composition of the compartment being investigated, as the effects on populations with high levels of T and B cells are likely different than the effects on populations of macrophages, neurons, and glia.

Specifically in the context of SIV, studies by Czub et al. have examined the impact of selegiline (i.e. deprenyl) on SIV-infected macaques. These data show that deprenyl treatment begun at two weeks after virus inoculation, at the peak of acute viremia, increased the extent of neuropathology, the number of SIV-infected cells, and inflammatory cytokine production in the brain. These changes were primarily observed in the basal ganglia, frontal cortex, and hippocampus, and included increased vacuolization, focal accumulations of lymphocytes and microglia cells, and an increase in mRNA for TNF-α (Czub et al., 2001, 2004). These effects were specifically linked to increases in CNS dopamine, caused by a decrease in the activity of both MAO-A and MAO-B activity, consistent with the administration of the drug by injection, as discussed above. Our prior data also show that dopamine increases HIV infection and inflammation in human macrophages and microglia, central drivers of HIV neuropathogenesis (Nickoloff-Bybel et al., 2019; Nolan et al., 2020). We have also shown that methamphetamine (Meth), which increases dopamine, exacerbates various aspects of CNS disease resulting from SIV infection in non-human primates (Marcondes et al., 2010; Najera et al., 2016; Niu et al., 2020), suggesting that dysregulated dopamine has a deleterious effect on neuroHIV (Nickoloff-Bybel et al., 2020).

In these experiments, deprenyl treatment increased CNS tissue levels of dopamine in the caudate and decreased DOPAC levels in the caudate, putamen, and substantia nigra, demonstrating that our deprenyl treatment functioned as expected. Interestingly, while we did not observe any significant interaction between deprenyl treatment and cortical dopamine indices, deprenyl did normalize prefrontal cortex serotonin tissue levels that were elevated following SIV infection. Serotonin can influence cognitive
function (Schmitt et al., 2006), but has a more well defined role in affect and mood disorders (Lin et al., 2014; Mann, 2013). This suggests that deprenyl may be more effective in the treatment of mood disorders than cognitive deficits associated with HIV infection. The aforementioned clinical trial (ACT5090) did not report any investigation of affect or mood disorders (Evans et al., 2007; Schifitto et al., 2007), suggesting a need for studies that characterize the efficacy of deprenyl treatment on affect or mood disorders that are often co-morbid with HIV infection (Beer et al., 2019; Camara et al., 2020; Nanni et al., 2015; Remien et al., 2019; Wang et al., 2018).

Surprisingly, we also found that SIV infection itself increased DA, DOPAC, HVA, and 5-HT in the frontal cortex, increased dopamine in the caudate, and increased 5-HT in the substantia nigra. Elevations in dopamine and 5-HT levels may be a product of increased synthesis of these neurotransmitters and increases in synthesis may subsequently result in greater metabolism and an elevation in metabolite levels. Studies in SIV-infected rhesus macaques and HIV-infected humans have also shown increases (Koutsilieri et al., 1997; Scheller et al., 2010) in dopamine and metabolite levels in the CSF. Thus, alterations in biogenic amine and metabolite levels observed in SIV infected monkeys may be a product of increased synthesis. However, this hypothesis is inconsistent with others studies showing decreased dopamine metabolite levels in the brain (Kumar et al., 2009) and CSF (di Rocco et al., 2000; Larsson et al., 1991; Saloner et al., 2020) of people living with HIV, as well as human PET imaging studies showing reduced DA signaling indices that correlate with cognitive symptoms in patients with HIV (Chang et al., 2008).

Alternatively, SIV-induced reductions in biogenic amine release may alter the compartmental distribution of biogenic amines and metabolites, resulting in increased tissue stores of these compounds. Brain biogenic amines and their metabolites are found in three separate compartments: (1) the cytosol of terminals, (2) vesicles within the cytosol of terminals, and (3) the extracellular space. Decreased biogenic amine release into the extracellular space due to reduced neuron firing, autoreceptor inhibition, or a disruption in vesicular packaging or release mechanisms could shift in the distribution of biogenic amines from the extracellular pool to either the cytosolic or vesicular pools (Best et al., 2009, 2010). Postmortem brain tissue collection procedures isolate the cytosolic and vesicular pools from the extracellular pool, thereby measuring only the biogenic amines and metabolites contained in the cytosolic and vesicular compartments. Thus, the observed reductions in dopamine and serotonin release would correspond with increases in brain tissue levels. This mechanism is consistent with preclinical studies showing that the HIV Tat protein can disrupt biogenic amine vesiculation by inhibition of the vesicular monoamine transporter (Midde et al., 2012), and that transgenic rats expressing HIV proteins display reduced dopamine and serotonin release capacity (Denton et al., 2019). Future studies should examine the mechanism by which SIV infection disrupts biogenic amine signaling, but these data indicate that SIV infection alone can disrupt biogenic amine processing and that the frontal cortex is particularly susceptible to this effect.

In contrast to prior macaque studies, the increases in dopamine we observed did not increase CNS viral load in the caudate or frontal cortex. Further, we observed decreased inflammatory gene expression in this region relative to increased inflammation in response to deprenyl and other dopamine-elevating drugs such as L-DOPA (Czub et al., 2001, 2004). Increases in neuropathology and CNS viral loads were also seen in macaques in response to Meth (Marcondes et al., 2010; Najera et al., 2016; Niu et al., 2020). The reason for the differences is not clear, but the distinct pathological effects of Meth, and other addictive substances, may be due to the substantially greater magnitude of dopamine release. In this study, in SIV-infected macaques, deprenyl increased caudate and frontal cortex dopamine by 59% and 56%, respectively. In contrast, amphetamine treatment in rhesus macaques increased dopamine 1000%–6000% in caudate and 600%–2000% in PFC as measured by microdialysis (Jedema et al., 2014), while a separate study showed direct injection of d-amphetamine into the caudate and PFC increased dopamine in each region by 1000%–1500% or 200%–500%, respectively (Saunders et al., 1994). The large difference between Meth and deprenyl-evoked dopamine release suggests that the differential pathology seen in these studies is due to the different magnitude of change in dopamine release. Also, direct comparison of these studies requires some caution, due to differences in experimental methodology, no specific report of dopamine concentrations in Meth studies and additional effects of Meth, such as impacts on blood–brain barrier permeability (Turowski and Kenny, 2015) and/or activation TAAR-1 receptors (Underhill et al., 2021).
The distinct timing and length of deprenyl treatment may also contribute to the differences between these studies and prior studies of SIV neuropathogenesis in deprenyl-treated macaques. In the current study, deprenyl treatment started one week prior to SIV inoculation and was maintained until 2 weeks post infection to examine the impact of deprenyl on the development of acute infection. The previous studies began treatment with deprenyl at two weeks post SIV inoculation and assessed output parameters at 8–20 weeks post infection. As the effects of deprenyl may be situational, the MAOI and non-MAOI-related effects of this drug could have been triggered by different environmental conditions, inflammatory milieu, and/or stage of disease at the time of treatment. Further studies delineating the specific mechanisms by which deprenyl can act will be needed to resolve these questions.

Another critical consideration is that the anti-inflammatory effects of deprenyl, while seemingly beneficial, were only seen during the acute phase of infection. Importantly, these acute anti-inflammatory effects could be detrimental to long-term disease outcomes. Some of the genes that were downregulated by deprenyl in the CNS were antiviral genes, including OAS2 and tetherin (BST2). Several other antiviral genes (MX1, MX2, and OAS1) were also significantly upregulated by SIV and downregulated more than 2-fold by deprenyl, although the deprenyl mediated decrease in these latter genes did not reach significance. Decreases in CNS antiviral genes could certainly result in the development of a more robust infection in this compartment, and a recent study noted an inverse correlation in expression of MX1, OAS1, and MX2 expression with SIV RNA levels in the CNS (Mohammadzadeh et al., 2021).

Previous studies in macaques have also shown that several of our results, including reduction in CD8⁺ T cells (Marcondes et al., 2015), decreases in IL-16 (Amiel et al., 1999) and an early blockade of inflammatory factors such as interferon stimulated genes (Sandler et al., 2014) can worsen disease progression in macaques. Notably, although CD8⁺ T cells are decreased by deprenyl, they are not reduced to the level induced in CD8-depletion experiments, so it is not clear that deprenyl-mediated CD8 reductions would result in the same sort of pathology. We also found a deprenyl-mediated increase in IL-6 at day 7, but this returned to baseline levels by day 14. We previously reported that IL-6 is increased in the periphery and CNS during SIV infection (Roberts et al., 2004), and that this is altered by depletion of CD8 cells (Madden et al., 2004). Other groups have also shown increased IL-6 correlates with more severe CNS disease in macaques (Gopalakrishnan et al., 2021; Witwer et al., 2009). However, the effects of increased IL-6 are mostly seen in respect to longer term elevation of this cytokine. Thus, the transient nature of the increase we observed in IL-6 makes it unclear whether this would have any impact on disease progression. Longitudinal studies examining disease course and changes in inflammatory factors over time will be required to determine if the impact of deprenyl-mediated anti-inflammatory effects is beneficial or deleterious in the longer term.

Limitations of the study
In addition to the potential confounds associated with the timing of deprenyl treatment and the potential for decreases in inflammation to worsen disease progression, this study has several other important limitations. As with many non-human primate studies, the sample size (n = 4) is a significant caveat, particularly because disease course and associated inflammation in both PLWH and SIV-infected macaques is robustly heterogeneous, with widely varying inflammatory effects and viral loads in untreated animals at the same timepoint during chronic disease. This small number of animals used in this study makes the results more susceptible to inter-animal heterogeneity and single outliers, particularly when correcting for multiple analyses or when the effect sizes are moderate or variable. To ameliorate somewhat these issues, macaques were sacrificed at two weeks post infection. In SIV infection, two weeks post infection is the most reproducible time in terms of viremia, as it generally represents peak viremia. This is predictive of set-point viremia and has much lower variability than measuring set-point and later levels of virus (Parker et al., 2001).

A second caveat is that the gene expression changes were defined using an immunology expression panel, so it is possible that other “non-immune”-associated genes were missed in this analysis. Many types of such genes, such as those regulating cellular metabolism, also strongly influence inflammatory activity, so a wider analysis of deprenyl-induced changes to gene expression in the context of SIV could improve our understanding of the pathways through which deprenyl downregulated inflammatory activity. Furthermore, genes and pathways involved in neuronal function were not studied and we only examined three brain regions and the spleen, while other areas of the brain and peripheral organs that can affect the brain and disease course were not examined.
SUMMARY
This study shows that the monoamine oxidase inhibitor deprenyl, an antidepressant with a long history of use in depression and Parkinson disease, has broad anti-inflammatory effects when given during the acute stage of SIV infection. Inflammation is a central factor in HIV-associated morbidity in the current era (Deeks et al., 2013b) and CNS inflammation is common in early infection and associated with the development of neuroHIV (Saylor et al., 2016; Valcour et al., 2012). These data suggest deprenyl as an attractive candidate for drug repurposing, as there is a critical need for new anti-inflammatory ART-adjuvants. Furthermore, the prevalence of depression in PLWH is high, deprenyl has a strong safety profile in HIV-infected individuals on ART (Evans et al., 2007; Schifitto et al., 2007), and its capacity to be administered transdermally improves longitudinal adherence and increases tolerability (Asnis and Henderson, 2014). These data also indicate that the anti-inflammatory mechanisms of MAOI class drugs deserve more attention, particularly with the growing amount of data linking inflammation to depression and the potential importance of anti-inflammatory treatments (Beurel et al., 2020; Dantzer et al., 2008; Kohler et al., 2016). A better understanding of these mechanisms could enable use of these well-known drugs for a variety of diseases, including HIV, and provide important insight into previously undefined pathways mediating inflammation.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Material availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Rhesus macaques, deprenyl treatment and SIV infection
- METHOD DETAILS
  - SIV plasma viral load quantification
  - Flow cytometry
  - Analysis of peripheral biomarkers
  - Analysis of monoamines and metabolites
  - SIV cell-associated RNA quantification from frozen tissues
  - Immunohistochemistry and RNAscope
  - NanoString and quantitative real-time PCR (qRT-PCR)
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.isci.2022.104207.

ACKNOWLEDGMENTS
We would like to thank Gaskill lab members Samyuktha Manikandan, Heidi Joyce, Krisna Mompho, and Breana Channer for helping with image processing. We would like to give a special thanks to Dr. Holly Moore, who provided critical guidance on the preservation of monoamines in tissue. We would also like to thank all the members of Gaskill and Fox labs for ongoing discussions that helped to formulate and synthesize the concepts discussed in this paper, as well as the DNA Sequencing (DNAS) and Flow Cytometry Research (FCR) at UNMC for assistance. This work was supported by the National Institutes of Health (R01DA039005 and R21DA049227 to PJG, R01DA04316 to HSF and SNB, R01DA043258 and P30MH062261 to HSF, R01DA031900 to RAE) and the W. W. Smith Charitable Trust (A2003 to PJG). The DNA Sequencing (DNAS) and Flow Cytometry Research (FCR) receive partial support from the NIH National Institute of General Medical Sciences INBRE P20GM103427 (DNAS), and COBRE P30GM110768 (DNAS) grants, NIH National Cancer Institute Cancer Support Grant P30CA036727 (FCR), and the Nebraska Research Initiative (FCR). Major instrumentation has been provided by the UNMC Office of the Vice Chancellor for Research, the University of Nebraska Foundation of N, the Nebraska Banker’s Fund, and by the NIH NCRR/NIGMS Shared Instrument Program.
AUTHOR CONTRIBUTIONS

PJG conceptualized the project; HSF and PJG designed the experiments; BM, BGL, and HSF maintained, treated, and processed the rhesus macaques; KR managed data and sample exchange between UNMC and Drexel; KME, KR, HSJ, and HSF performed and processed the immunohistochemistry and RNAscope in situ hybridization; KME isolated RNA for viral load and NanoString analysis; BM performed the flow cytometry; AA and SNB performed the analysis of plasma and tissue viral load; ZDB and RAE performed the HPLC analysis of CNS monoamines; HSF and PJG analyzed the data; PJG wrote the original manuscript; KME, ZDB, KR, BM, HSF, and PJG edited the manuscript and all authors edited and approved of the final submission.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

Abdanipour, A., Jafari Anarkooli, J., Shokri, S., Ghorbanliou, M., Bayati, V., and Nejabatkhah, R. (2018). Neuroprotective effects of selegiline on rat neural stem cells treated with hydrogen peroxide. Biomed. Rep. 8, 41–46.

Acharya, A., Olvernyi, O.A., Thurman, M., Pandey, K., Morsey, B.M., Lamberty, B., Ferguson, N., Callen, S., Fang, Q., Buch, S.J., et al. (2020). Chronic morphine administration differentially modulates viral reservoirs in SIVmac251 infected rhesus macaque model. J. Virol. 95, e01657-20.

Adland, E., Mori, L., Laker, L., Csaia, A., Muenchhoff, M., Swordy, A., Mori, M., Matthews, P., Tudor-Williams, G., Jooste, P., et al. (2018). Recovery of effective HIV-specific CD4+ T-cell response requires sustained suppression of HIV replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. J. Infect. Dis. 179, 83–91.

Asnis, G.M., and Henderson, M.A. (2014). EMSAM (deprenyl patch): how a promising antidepressant was underutilized. Neuropsychiatr. Dis. Treat 10, 1911–1923.

Beer, L., Tie, Y., Padilla, M., Shouse, R.L., and Medical Monitoring, P. (2019). Generalized anxiety disorder symptoms among persons with diagnosed HIV in the United States. AIDS 33, 1781–1787.

Bekesi, G., Tulassay, Z., Lengyel, G., Schaff, Z., Szombath, D., Stark, J., Marczell, I., Nagy-Repas, P., Adler, I., Dinya, E., et al. (2012). The effect of selegiline on total scavenger capacity and liver fat content: a preliminary study in an animal model. J. Neural Transm. (Vienna) 119, 25–30.

Best, J., Reed, M., and Nijhout, H.F. (2010). Models of dopaminergic and serotonergic signaling. Pharmacopsychiatry 43, S61–S66.

Best, J.A., Nijhout, H.F., and Reed, M.C. (2009). Homeostatic mechanisms in dopamine synthesis and release: a mathematical model. Theor. Biol. Med. Model 6, 21.

Beurel, E., Toups, M., and Nemeroff, C.B. (2020). The bidirectional relationship of depression and inflammation: double trouble. Neuron 107, 234–256.

Bhatia, M.S., and Munjal, S. (2014). Prevalence of depression in people living with HIV/AIDS undergoing ART and factors associated with it. J. Clin. Diagn. Res. 8, WC01-04.

Bielecka, A.M., Paul-Samojedny, M., and Obuchowicz, E. (2010). Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture. Naunyn Schmiedebergs Arch. Pharmacol. 382, 409–417.

Billett, E.E. (2004). Monoamine oxidase (MAO) in human peripheral tissues. Neurotoxicology 25, 139–148.

Brodnik, Z.D., Black, E.M., Clark, M.J., Kornsey, K.N., Snyder, N.W., and Espana, R.A. (2017a). Susceptibility to traumatic stress sensitizes the dopaminergic response to cocaine and increases motivation for cocaine. Neuropharmacology 125, 295–307.

Brodnik, Z.D., Double, M., Espana, R.A., and Jaskiw, G.E. (2017b). L-Tyrosine availability affects basal and stimulated catecholamine indices in prefrontal cortex and stratum of the rat. Neuropharmacology 123, 159–174.

Byrareddy, S.N., Kallam, B., Arthos, J., Cicala, C., Nawaz, F., Hiatt, J., Kersh, E.N., McNicholl, J.M., Hanson, D., Reimann, K.A., et al. (2014). Targeting alpha4beta7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection. Nat. Med. 20, 1397–1400.

Byrnes-Blake, K.A., Pederson, S., Klucher, K.M., Anderson-Haley, M., Miller, D.M., Lopez-Talavera, J.C., and Freeman, J.A. (2012). Pharmacokinetics and pharmacodynamics of pegylated interferon lambda-1 in cynomolgus monkeys. J. Interferon Cytokine Res. 32, 198–206.

Camara, A., Sow, M.S., Toure, A., Sako, F.B., Camara, I., Soumaoro, K., Delamou, A., and Doukoure, M. (2020). Anxiety and depression among HIV patients of the infectious disease department of Conakry University Hospital in 2018. Epidemiol. Infect. 148, e6.

Chang, L., Wang, G.J., Vollkow, N.D., Ernst, T., Telang, F., Logan, J., and Fowler, J.S. (2008). Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. Neurommage 42, 869–878.

Cline, A.N., Bess, J.W., Piatak, M., Jr., and Ulfson, J.D. (2005). Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol 34, 303–312.

Collins, L.F., and Armstrong, W.S. (2020). What it means to age with HIV infection: years gained are not comorbidity free. JAMA Netw. Open 3, e208023.

Cook, J.A., Burke-Miller, J.K., Steigman, P.J., Schwartz, R.M., Hessol, N.A., Milam, J., Merenstein, D.J., Anastos, K., Golub, E.T., and Cohen, M.H. (2018). Prevalence, comorbidity, and correlates of psychiatric and substance use disorders and associations with HIV risk behaviors in a multisite cohort of women living with HIV. AIDS Behav. 22, 3141–3154.

Received: November 2, 2021
Revised: February 28, 2022
Accepted: April 1, 2022
Published: May 20, 2022
Cui, Y., Liu, K.W., Liang, Y., Ip, M.S., and Mak, J.C. (2017). Inhibition of monoamine oxidase-B by selegiline reduces cigarette smoke-induced oxidative stress and inflammation in airway epithelial cells. Toxicol. Lett. 268, 44–50.

Czub, S., Czub, M., Koutsilieri, E., Sopper, S., Villinger, F., Muller, J.G., Stahl-Hennig, C., Riederer, P., Ter Meulen, V., and Gosztonyi, G. (2004). Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs. Acta Neuropathol. 107, 216–226.

Czub, S., Koutsilieri, E., Sopper, S., Czub, M., Stahl-Hennig, C., Muller, J.G., Pedersen, V., Gisell, W., Heeney, J.L., Gerlach, M., et al. (2001). Enhancement of central nervous system function in HIV-1-infected patients. Clin. Cancer Res. 7, 285–289.

Ekdun, D., Firth, J.D., Nayer, T., Tomofuji, T., Sanbe, T., Irie, K., Yamamoto, T., Oka, T., Liu, Z., Vellkind, J., et al. (2009). Lipopolysaccharide-induced epithelial monoamine oxidase mediate alveolar bone loss in a rat chronic wound model. Am. J. Pathol. 173, 1398–1409.

Evans, S.R., Yeh, T.M., Sacktor, N., Clifford, D.B., Simpson, D., Miller, E.N., Ellis, R.J., Valcour, V., Marra, C.M., Millar, L., et al. (2007). Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin. Trials 8, 437–446.

Farahat, F.M., Alghamdi, Y.S., Farahat, A.F., Alquarashi, A.A., Albarkiy, A.A., Alsaedi, A.A., and Alshammarni, M.M. (2020). The prevalence of comorbidities among adult people diagnosed with HIV infection in a tertiary care hospital in western Saudi Arabia. J. Infect. Public Health 13, 1699–1704.

Finberg, J.P., and Rabey, J.M. (2016). Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front. Pharmacol. 7, 340.

Fowler, J.S., Logan, J., Volkow, N.D., Shumay, E., McCall-Perez, F., Jayne, M., Wang, G.J., Alexoff, D.L., Apelagoks-Torres, K., Hubbard, B., et al. (2011). Evidence that formulations of the selective MAO-B inhibitor, selegeline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology 40, 650–657.

Freiberg, M.S., Chang, C.C., Keller, L.H., Skanderson, M., Lowy, E., Kraemer, K.L., Butt, A.A., Bidwell Goetz, M., Leaf, D., Oursler, K.A., et al. (2013). HIV infection and the risk of acute myocardial infarction. JAMA Intern. Med. 173, 614–622.

Funderburg, N.T. (2014). Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr. Opin. HIV AIDS 9, 80–86.

Funke, B., Spinner, C.D., Wolf, E., Heiken, H., Kitani, K., Kanai, S., Carrillo, M.C., and Ivy, G.O. (1994). (±)Deprenyl increases the life span as well as activities of superoxide dismutase and catalase but not of glutathione peroxidase in selective brain regions in Fischer rats. Ann. N. Y Acad. Sci. 717, 60–71.

Kanai, S., Carrillo, M.C., Ivy, G.O., and Carrillo, M.C. (1998). Assessing the effects of deprenyl on longevity and antioxidant defenses in different animal models. Ann. N. Y Acad. Sci. 854, 291–306.

Kanai, S., Minami, C., Yamamoto, T., Maruyama, W., Kanai, S., Ivy, G.O., and Carrillo, M.C. (2001). Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy. Ann. N. Y Acad. Sci. 928, 248–260.

Kanai, S., Ivy, G.O., and Carrillo, M.C. (1996). Phenylnisopropylmethylpropionylamine (E-250), a new spectrum psychic energizer. Arch. Int. Pharmacodyn Ther. 175, 154–164.

Kanai, S., and Mikiya, I. (2016). Longevity study with low doses of selegeline(-)-depenryl and 2(3)-1-(benzofuran-2-yl)-N-propylpentane-2-amine (BPAP). Life Sci. 167, 32–38.

Kobayashi, S.D., Olsen, R.J., Lecasere, R.A., Safonets, D., Ashraf, M., Porter, A.R., Braughton, K.R., Feldmann, F., Clifton, D.R., Kash, J.C., et al. (2013). Seasonal H3N2 influenza A virus fails to enhance Staphylococcus aureus co-infection in a non-human primate respiratory tract infection model. Virulence 4, 707–715.

Kohler, O., Krog, J., Mors, O., and Benros, M.E. (2016). Inflammation in depression and the
potential for anti-inflammatory treatment. Curr. Neuropharmacol 14, 732–742.

Kong, A.M., Pozen, A., Anastos, K., Kelvin, E.A., and Nash, D. (2019). Non-HIV comorbid conditions and polypharmacy among people living with HIV age 65 or older compared with HIV-negative individuals age 65 or older in the United States: a retrospective claims-based analysis. AIDS Patient Care STDS 33, 93–103.

Korencak, M., Byrne, M., Richter, E., Schultz, B.T., Juszcak, P., Ake, J.A., Ganesan, A., Okulicz, J.F., Robb, M.L., de Los Reyes, B., et al. (2019). Effect of HIV infection and antiretroviral therapy on immune cellular functions. J Clin. Insight 4.

Koutsilieri, E., Chen, T.S., Rausch, W.D., and Riederer, P. (1996). Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium. Eur. J. Pharmacol. 306, 181–186.

Koutsilieri, E., Gotz, M.E., Sopper, S., Stahl-Hennig, C., Czub, M., ter Meulen, V., and Riederer, P. (1997). Monoamine metabolite levels in CSF of SIV-infected rhesus monkeys (Macaca mulatta). Neuroreport 8, 3633–3636.

Koutsilieri, E., O’Callaghan, J.F., Chen, T.S., Riederer, P., and Rausch, W.D. (1994). Selegiline enhances survival and neurite outgrowth of MPP(+) -treated dopaminergic neurons. Eur. J. Pharmacol. 269, R3–R4.

Kragten, E., Lalande, I., Zimmermann, K., Roogo, S., Schindler, P., Muller, D., van Oostrum, J., Lamberty, B.G., Flynn, C.T., and Fox, H.S. (2015). Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. Am. J. Pathol. 177, 355–361.

Kumar, A.M., Fernandez, J.B., Singer, E.J., Commis, D., Waldrop-Valverde, O., Ownby, R.L., and Kumar, M. (2009). Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J. Neurovirol. 15, 257–274.

Larsson, M., Hagberg, L., Forsman, A., and Norkrans, G. (1991). Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. J. Neurosci. Res. 28, 406–409.

Lieb, J. (1983). Remission of rheumatoid arthritis and other disorders of immunity in patients taking monooamine oxidase inhibitors. Int. J. Immunopharmacol. 5, 353–357.

Lin, A., Song, C., Kenis, G., Bosmans, E., De Jongh, R., Scharpe, S., and Maes, M. (2000). The in vitro immunosuppressive effects of moclobemide in healthy volunteers. J. Affect Disord. 58, 69–74.

Lin, S.-H., Lee, L.-T., and Yang, Y.K. (2014). Serotonin and mental disorders: a concise review on molecular neuroimaging evidence. Clin. Psychopharmacol. Neurosci. 12, 196.

Lorenc, A., Ananthavathar, P., Lorigan, J., Jowata, M., Brook, G., and Banarsee, R. (2014). The prevalence of comorbidities among people living with HIV in Brent: a diverse London Borough. Lond. J. Prim Care (Abingdon) 6, 84–90.

Macle, R.A., Klick, H.M., Durand, M., and Sprinz, E. (2018). Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: a cross-sectional study. Int. J. Infect. Dis. 70, 30–35.

Madden, L.J., Zandonatti, M.A., Flynn, C.T., Taffe, M.A., Marcondes, M.C., Schmitz, J.E., Reinmann, K.A., Henriksen, S.J., and Fox, H.S. (2004). CD8+ cell depletion amplifies the acute retroviral syndrome. J. Neurovirol. 10, 58–66.

Mann, J.J. (2013). The serotonergic system in mood disorders and suicidal behaviour. Philosophical Trans. R. Soc. B. Biol. Sci. 368, 20120537.

Mann, J.J., and Currier, D. (2007). A review of serotonin and mental disorders: a concise review on molecular neuroimaging evidence. Clin. Psychopharmacol. Neurosci. 12, 53–60.

Moffitt, T., and Nagin, D. (2001). Using latent class analysis. AIDS Patient Care STDS 15, 73–115.

Mohammedzadeh, N., Rooda, W., Branton, W.G., Clain, J., Rabezazhany, H., Zghidi-Abouzid, O., Gelman, B.B., Angel, J.B., Cohen, E.A., Gill, M.J., et al. (2021). Lentiviral infections persist in brain despite effective antiretroviral therapy and neuroimmune activation. mBio 12, e0278421.

Morsal, D., Bechtold, D., Lee, W., Chaudry, S., Palchaudhuri, U., Hassoon, P., Snell, D.M., Malpass, K., Piets, T., Posch, J., et al. (2013). Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. Brain 136, 1067–1082.

Nagatsu, T., and Sawada, M. (2006). Molecular mechanism of the relation of monooamine oxidase B and its inhibitors to Parkinson’s disease: possible implications of glial cells. J. Neural Transm. 71, 53–65.

Nagy, C.T., Koncso, G., Varga, Z.V., Baranyai, T., Kus, T., Kiss, F., Enyedi, A., Gyertyan, I., Kiraly, K., Olah, A., et al. (2018). Selegiline reduces adiposity induced by high-fat, high-sucrose diet in male rats. Br. J. Pharmacol. 175, 3713–3726.

Naicker, S., Rahmanian, S., and Kopp, J.B. (2015). HIV and chronic kidney disease. Clin. Nephrol. 83, 32–38.

Najera, J.A., Bustamante, E.A., Bortell, N., Morsey, B., Fox, H.S., Ravasi, T., and Marcondes, M.C. (2016). Methamphetamine abuse affects gene expression in brain-derived microglia of SV-infected macaques to enhance inflammation and promote virus targets. BMC Immunol. 17, 7.

Nanni, M.G., Caruso, R., Mitchell, A.J., Meggiolaro, E., and Grassi, L. (2015). Depression in HIV infected patients: a review. Curr. Psychiatry Rep. 17, 530.

Negin, J., Martiniuk, A., Cumming, R., Naidoo, N., Phaswana-Mafuya, N., Madurai, L., Williams, S., and Kowal, P. (2012). Prevalence of HIV and chronic comorbidities among older adults. AIDS 24, 555–563.

Nickoloff-Bybel, E.A., Calderon, T.M., Gaskill, P.J., and Berman, J.W. (2020). HIV neuropathogenesis in the presence of a disrupted dopamine system. J. Neuroimmune Pharmacol. 15, 729–742.

Nickoloff-Bybel, E.A., Mackie, P., Runner, K., Matt, S.M., Khoshbouei, H., and Gaskill, P.J. (2019). Dopamine increases HIV entry into macrophages by increasing calcium release via an alternative signaling pathway. Brain Behav. Immun. 82, 239–252.

Niu, M., Morsey, B., Lamberty, B.G., Emanuel, K., Yang, X., Lemmon, B., Berman, J.W., Gaskill, P.J., Matt, S.M., Ciborowski, P.S., et al. (2020). Methamphetamine increases the proportion of SV-infected microglia/macrophages, alters metabolic pathways, and elevates cell death pathways: a single-cell analysis. Viruses 12, 1297.

Nolan, R.A., Reeb, K.L., Rong, Y., Matt, S.M., Johnson, H.S., Runner, K., and Gaskill, P.J. (2020). Dopamine activates NFKappaB and primes the NLRP3 inflammasome in primary human macrophages. Brain Behav. Immun. 2, 100030.

Olson, R.J., Ashraf, M., Gounal, V.E., Ayers, A.A., Cantu, C., Shea, P.R., Carroll, R.K., Humbird, T., Greaver, J.L., Swain, J.L., et al. (2010). Lower respiratory tract infection in cynomolgus
macaques (Macaca fascicularis) infected with group A Streptococcus. Microb. Pathog. 49, 336–347.

Parker, R.A., Regan, M.M., and Reimann, K.A. (2001). Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics. J. Virol. 75, 11234–11238.

Pelchen-Matthews, A., Ryom, L., Borges, A.H., Edwards, S., Durvieux, C., Stephan, C., Sambatakou, H., Maciejewski, K., Portu, J.J., Weber, J., et al. (2018). Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort. AIDS 32, 2405–2416.

Perazzo, H., and Luz, P.M. (2017). Liver disease and healthy life expectancy with HIV. Lancet HIV 4, e236–e237.

Peterson, T.E., and Baker, J.V. (2019). Assessing inflammation and its role in comorbidities among persons living with HIV. Curr. Opin. Infect. Dis. 32, 8–15.

Pinheiro, C.A., Souza, L.D., Motta, J.V., Kelbert, E.F., Souza, M.S., Martins, C.S., Coelho, F.M., Pinheiro, K.A., and Pinheiro, R.T. (2016). Depression and diagnosis of neurocognitive impairment in HIV-positive patients. Braz. J. Med. Biol. Res. 49, e5344.

Pourcher, V., Gourmelen, J., Bureau, I., and Boue, S. (2020). Comorbidities in people living with HIV: an epidemiologic and economic analysis using a claims database in France. PLoS One 15, e0243529.

Ratni, C., Utsu, D., Petrus, A., Norbert, P., Olariu, S., Duico, O., Sturza, A., and Muntene, D.M. (2018). Monoamine oxidase inhibition improves vascular function and reduces oxidative stress in rats with ischemiасaсhide-induced inflammation. Gen. Physiol. Biophys. 37, 687–694.

Regidor, D.L., Detels, R., Breen, E.C., Widney, D.P., Jacobson, L.P., Letendre, S.L., Kumar, A., Grant, I., and Ellis, R.J. (2020). Lower CSF homovanillic acid relates to higher burden of neuroinflammation and depression in people with HIV disease. Brain Behav. Immun. 90, 353–363.

Sanchez-Rodriguez, R., Munari, F., Angioni, R., Venegas, F., Agnellini, A., Castro-Gil, M.P., Castegna, A., Lussetto, R., Viola, A., and Canton, M. (2020). Targeting monoamine oxidase to dampen NLRP3 inflammasome activation in inflammation. Cell Mol Immunol 18, 1311–1313.

Sandler, N.G., Bosingher, S.E., Estes, J.D., Zhu, R.T., Tharp, G.K., Boritz, E., Levin, D., Miyake, S., Makamadp, K.N., Del Prete, G.A., et al. (2014). Type 1 interferon responses in rhes macaques prevent SIV infection and slow disease progression. Nature 517, 601–605.

Saunders, R.C., Kolachana, B.S., and Weinberger, D.R. (1994). Local pharmacological manipulation of extracellular dopamine levels in the dorsolateral prefrontal cortex and caudate nucleus in the rhesus monkey: an in vivo microdialysis study. Exp. Brain Res. 98, 44–52.

Schell, A., Arendt, G., Nohting, T., Antke, C., Sopper, S., Maschke, M., Obermann, M., Angerer, A., Husstedt, I.W., Messner, F., et al. (2010). Increased dopaminergic neurotransmission in therapy-naive asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. J. Neural Transm. (Vienna) 117, 699–705.

Selegeline and oxidative stress in HIV-associated cognitive impairment. Neurology 72, 1975–1981.

Shifflett, G., Zhang, J., Evans, S.R., Sacktor, N., Simpson, D., Millar, L.C., Hung, V.L., Miller, E.N., Smith, E., Ellis, R.J., et al. (2007). A multicenter trial of selegline transdermal system for HIV-associated cognitive impairment. Neurology 69, 1314–1321.

Schmitt, J., Wingen, M., Ramaekers, J., Evers, E., and Riedel, W. (2006). Serotonin and human cognitive performance. Curr. Pharm. Des. 12, 2473–2486.

Seresi, I., Krebs, S.J., Phanuphak, N., Fletcher, J.L., Silke, B., Pinyakorn, S., O’Connell, R.J., Rupert, A., Chomont, N., Valcour, V., et al. (2017). Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection. Clin. Infect. Dis. 64, 124–131.

Shen, L., Engelhardt, J.A., Hung, G., Yee, J., Kikkawa, R., Matson, J., Tayefeh, B., Machemer, T., Gudaa, P.C., and Heretz, S.P. (2016). Effects of repeated complement activation associated with chronic treatment of cynomolgus monkeys with 2-O-methoxyethyl modified antisense oligonucleotide. Nuclear Acid Ther. 26, 236–249.

Shiau, S., Arpadi, S.M., Yin, M.T., and Martins, S.S. (2017). Patterns of drug use and HIV infection among adults in a nationally representative sample. Addict Behav. 68, 39–44.

Shive, C.L., Biancotto, A., Funderburk, N.T., Pitch-Cooper, H.A., Valdez, H., Margolis, L., Sieg, S.F., McComsey, G.A., Rodriguez, B., and Lederman, M.M. (2012). HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. J. Acquir. Immune Defic Syndr. 61, 145–152.

Sivasubramanian, S.D., Finch, C.C., Rodriguez, M.J., Mahy, N., and Billett, E.E. (2003). A comparative study of the expression of monoamine oxidase A and B mRNA and protein in non-CNS human tissues. Cell Tissue Res. 313, 291–300.

Smit, M., Brinkman, K., Geerlings, S., Smit, C., Thyagarajan, K., Sighem, A., de Wolf, F., Hallett, T.B., and cohort, A.o. (2015). Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect. Dis. 15, 810–818.

Sturza, A., Leisegang, M.S., Babelova, A., Schroder, K., Benklof, S., Loot, A.E., Fleming, I., Schulz, R., Muntene, D.M., and Brandes, R.P. (2013). Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta. Hypertension 62, 140–146.

Szego, E., Tabi, T., Riederer, P., Vecsei, L., and Magyar, K. (2018). Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegeline and rasagiline, in Parkinson’s disease. J. Neural Transm. (Vienna) 125, 1735–1749.

Tabakman, R., Lecht, S., and Lazarovic, P. (2004). Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson’s disease? Bioessays 26, 80–90.

Tatton, W.G., and Chalmers-Redman, R.M. (1996). Modulation of gene expression rather
than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47, S171–S183.

Tatton, W.G., Ju, W.Y., Holland, D.P., Tai, C., and Kwan, M. (1994). (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63, 1572–1575.

Tatton, W.G., Wadia, J.S., Ju, W.Y., Chalmers-Redman, R.M., and Tatton, N.A. (1996). (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J. Neural Transm. Suppl. 48, 45–59.

Tazik, S., Johnson, S., Lu, D., Johnson, C., Youdim, M.B., Stockmeier, C.A., and Ou, X.M. (2009). Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox Res. 15, 284–290.

Temu, T.M., Zifodya, J.S., Polyak, S.J., Wagoner, J., Wanjalla, C.N., Masyuko, S., Nyabiage, J., Kinuthia, J., Bloomfield, G.S., Page, S.T., et al. (2021). Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya. AIDS 35, 45–51.

Triant, V.A., Lee, H., Hadigan, C., and Grinspoon, S.K. (2007). Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J. Clin. Endocrinol. Metab. 92, 2506–2512.

Tsao, C.M., Jhang, J.G., Chen, S.J., Ka, S.M., Wu, T.C., Liaw, W.J., Huang, H.C., and Wu, C.C. (2014). Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis. PLoS One 9, e108455.

Turowski, P., and Kenny, B.A. (2015). The blood-brain barrier and methamphetamine: open sesame? Front. Neurosci. 9, 156.

UNAIDS (2013). HIV and Aging: A special supplement to the UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS (UNAIDS). (UNAIDS).

Underhill, S.M., Hullihen, P.D., Chen, J., Fenollar-Ferrer, C., Rizzo, M.A., Ingram, S.L., and Amara, S.G. (2021). Amphetamines signal through intracellular TAAR1 receptors coupled to Galpha13 and GalphaS in discrete subcellular domains. Mol. Psychiatry 26, 1208–1223.

Valcour, V., Chalermchai, T., Sailsuta, N., Marovich, M., Lerdulum, S., Suttichom, D., Suwanwela, N.C., Jagodzinski, L., Michael, N., Spudich, S., et al. (2012). Central nervous system viral invasion and inflammation during acute HIV infection. J. Infect. Dis. 206, 275–282.

Wada, N.I., Jacobson, L.P., Margolick, J.B., Breen, E.C., Macatangay, B., Penugonda, S., Martinez-Maza, O., and Bream, J.H. (2015). The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 29, 463–471.

Wang, T., Fu, H., Kaminga, A.C., Li, Z., Guo, G., Chen, L., and Li, Q. (2018). Prevalence of depression or depressive symptoms among people living with HIV/AIDS in China: a systematic review and meta-analysis. BMC Psychiatry 18, 160.

Warren, J.A., Clutton, G., and Goonetilleke, N. (2019). Harnessing CD8(+) T cells under HIV antiretroviral therapy. Front. Immunol. 10, 291.

Witwer, K.W., Gama, L., Li, M., Bartizal, C.M., Queen, S.E., Varrone, J.J., Brice, A.K., Graham, D.R., Tarwater, P.M., Mankowski, J.L., et al. (2009). Coordinated regulation of SIV replication and immune responses in the CNS. PLoS One 4, e8129.

Yang, H.Y., Beymer, M.R., and Suen, S.C. (2019). Chronic disease onset among people living with HIV and AIDS in a large private insurance claims dataset. Sci. Rep. 9, 18514.

Yao, Y., Luo, Y., He, Y., Zheng, Y., Zhang, Q., Zhou, H., Zeng, S., Chen, Z., He, B., and He, M. (2013). The effect of a year of highly active antiretroviral therapy on immune reconstruction and cytokines in HIV/AIDS patients. AIDS Res. Hum. Retroviruses 29, 691–697.

Zanni, M.V., Toribio, M., Robbins, G.K., Burdo, T.H., Lu, M.T., Ishai, A.E., Feldpausch, M.N., Martin, A., Melbourne, K., Triant, V.A., et al. (2016). Effects of antiretroviral therapy on immune function and arterial inflammation in treatment-naïve patients with human immunodeficiency virus infection. JAMA Cardiol. 1, 474–480.
### Star Methods

#### Key Resources Table

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| BV605 Anti-mouse/human CD11b, clone M1/70  | BioLegend | Cat# 101257, RRID: AB_2565431 |
| BV421 Mouse anti-human CD3, clone SP34 | BD Biosciences | Cat# 562877, RRID: AB_2737860 |
| BV786 Mouse anti-human CD4, clone L200 | BD Biosciences | Cat# 563914; RRID: AB_2738485 |
| PeCy7 Mouse anti-human CD8, clone RPAT8 | BD Biosciences | Cat# 557746; RRID: AB_396852 |
| ECD Mouse anti-human CD14, clone RM052 | Beckman Coulter | Cat# IM2070U; RRID: AB_130853 |
| APCH7 Mouse anti-human CD16, clone 3G8 | BD Biosciences | Cat# 560195; RRID: AB_1645466 |
| BV711 Mouse anti-human CD20, clone 2H7 | BD Biosciences | Cat# 563126, RRID: AB_2313579 |
| Iba-1, rabbit polyclonal antibody | Fujifilm Wako Pure Chemical Corporation | Cat# 019-19741; RRID: AB_839504 |
| **ImmPress – HRP Horse Anti-Rabbit IgG Polymer Reagent** | Vector Laboratories | Cat# MP-7401; RRID: AB_2336529 |
| **Bacterial and virus strains** |        |            |
| SIVmac251 (passaged through brain microglia and Chinese origin rhesus macaques) | H.S Fox, UNMC, Omaha, NE | N/A |
| **Chemicals, peptides, and recombinant proteins** |        |            |
| Glacial Acetic Acid, HPLC grade | Thermo Fisher | A35-500 |
| TRIzol | Life Technologies | Cat# 15596026 |
| DNTPs | Invitrogen | Cat# 18091050 |
| SuperaseIN | Invitrogen | Cat# AM2696 |
| Superscript/5X Buffer/0.1M DTT: Kit | Invitrogen | Cat# 18090010 |
| Red blood cell lysis buffer | Sigma Aldrich | Cat# 11814389001 |
| Nova Red | Vector Laboratories | Cat# 5K-4805 |
| Hematoxylin QS | Vector Laboratories | Cat# H-3404 |
| Flow cytometry Buffer | eBioscience | Cat# 00-422-26 |
| Brilliant stain buffer | BD Biosciences | Cat# 563794 |
| **Critical commercial assays** |        |            |
| nCounter NHP Immunology expression panel | NanoString | Cat#NS_NHP_IMMUNOLOGY_V2.0 |
| Taqman RNA-to-CT One-Step Kit - RNA (qPCR) | Thermo Fisher Scientific | Cat# 4392938 |
| one-step RT ddPCR Advanced kit for probes (500 rxns) | BioRad | Cat# 1864022 |
| QiaGen RNeasy Mini Kit | QiaGen | Cat# 74106 |
| QIAGEN Viral RNA mini kit | QIAIEN | Cat# 52906 |
| Live Dead assay UV blue | Invitrogen | Cat# L23105 |
| 2.5 HD RED Assay | Advanced Cell Diagnostics | Cat# 322360 |
| **Experimental models: Organisms/strains** |        |            |
| Chinese origin rhesus macaques | PrimGen | http://www.primgen.com/ |
| **Oligonucleotides** |        |            |
| Primer probe set MX1 | Thermo Fisher Scientific | Cat# Rh02842279_m1 |
| Primer probe set ALAS1 | Thermo Fisher Scientific | Cat# Rh02829381_m1 |
| Primer probe set CXCL11 | Thermo Fisher Scientific | Cat# Rh02621763_m1 |
| Primer probe set OAZ1 | Thermo Fisher Scientific | Cat# Rh02809570_gH |
| Primer probe set IRF1 | Thermo Fisher Scientific | Cat# Rh00971962_m1 |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed and will be fulfilled by the lead contact, Peter J. Gaskill (pjg63@drexel.edu).

Material availability
This study did not generate new unique reagents.

Data and code availability
● All data reported in this paper will be shared by the Lead contact upon request.
● This paper does not report original code.
● Any additional information required to reanalyze the data reported in this paper is available from the Lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Rhesus macaques, deprenyl treatment and SIV infection
Sixteen male rhesus macaques (Macaca mulatta) of Chinese origin, which were SIV, simian retrovirus type D, simian T cell leukemia virus, and herpes B (Macacine alphaherpesvirus 1) virus-free were purchased from PrimGen (Hines, IL). The macaques were an average of 5 years old at necropsy, with a range of 3.5–6.75 years of age. All experiments had the approval from University of Nebraska Medical Center and Drexel University Institute Animal Care and Use Committees and followed the animal use guidelines set by the National Institutes of Health. Macaques were housed in compliance with the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals in the non-human primate facilities at Department of Comparative Medicine, University of Nebraska Medical Center (UNMC). The primate facility at UNMC has been accredited by the AAALAC international. This study was reviewed and approved by the UNMC Institutional Animal Care and Use Committee under protocol 16-020-04-FC entitled “Mechanism of drug abuse mediated SIV neuropathogenesis and immune dysregulation” approved 4/16/2016. Animals were maintained in a temperature-controlled (23 ± 2°C) indoor climate with 12-h light/dark cycle and fed Teklad Global 25% protein primate diet (Envigo, St. Louis, MO) supplemented with fresh fruit or vegetables, and...
Following quarantine, animals were acclimated to intramuscular injections for 2–3 weeks using positive reinforcement. Animals, kept in containment, were anesthetized with 10–15 mg/kg of ketamine intramuscularly before procedures. Animals were treated with vehicle (saline) or 2 mg/kg R-(−)-Deprenyl hydrochloride in saline (Sigma-Aldrich, St. Louis, MO) starting 1 week prior to infection as described in the Results. Animals were inoculated with 10^7 RNA copies of a stock SIVmac251 prepared in laboratory of Howard Fox, derived by serial passage in vivo through brain microglia and then through the blood of Chinese origin macaques (Burdo et al., 2005). The stock of SIVmac251 was diluted in a total of 3 mL RPMI 1640 (Invitrogen, Carlsbad, CA) and animals inoculated intravenously. Necropsy was performed 14 days after SIV inoculation by terminal anesthesia using overdose of ketamine and xylazine, consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. To protect monoamines in the brain tissue from oxidation, at necropsy, macaques were intracardially perfused with ice-cold 50% HeGA (glacial acetic acid (10–1 M), EDTA (10–4 M), 0.12% glutathione)/50% isotonic saline solution (pH 6). Brains were removed and rapidly dissected on ice, separating caudate, putamen, substantia nigra, corpus callosum, cerebellum, hippocampus, and frontal cortex.

METHOD DETAILS

SIV plasma viral load quantification

SIV RNA in the plasma was quantified by using quantitative reverse transcription-PCR (qRT-PCR) using our established protocols (Acharaya et al., 2020). Plasma was separated from blood samples collected in K2-EDTA vacutainer tubes (Becton Dickinson, San Diego, CA) within 4 h of collection. CSF was collected by cisterna magna puncture using a 22-gauge needle and dripped into a microfuge tube. RNA was extracted from 140 μL of plasma or CSF using a QIAamp Viral RNA mini kit according to manufacturer’s instructions (QIAGEN Germantown, MD). RNA was eluted in 50 μL of Buffer AVE. SIV gag RNA was quantified by qRT-PCR using the TaqMan RNA-to-Ct 1-Step Kit (Thermo Fisher Scientific, MA and Applied Biosystems QuantStudio3 Real-Time PCR System (Applied Biosystems, Waltham, MA). The reaction mix contained 12.5 μL of 2X Taq Buffer, 0.63 μL of 40X enzyme, 7.12 μL of nuclease-free water (Invitrogen, San Diego CA), 1 μL of 10 μM forward primer (5’-GTCTGCTCATCTGGCATTC-3’), 1 μL of 10 μM reverse primer (5’-CAG/ZEN/TGT GTC ATT TCT CTT CTG CG/3IABkFQ/–3I), and 0.25 μL of 10 μM probe (5’–/56-FAM/CTT CCT CAG/ZEN/TGT GTC ATT TCT CTT CTG CG/3IABkFQ/–3I), all custom from Integrated DNA Technologies (ITD), Coralville, IA. The thermal cycling conditions of the reaction were 48°C for 15 min, 95°C for 15 min and 40 cycles of 95°C for 15 s and 60°C for 1 min (data collection) (Byrareddy et al., 2014; Cline et al., 2005).

Flow cytometry

Flow cytometry evaluation was completed on peripheral whole blood from all study subjects. Blood was assessed at 2 weeks prior and the equivalent of day 0, 7 and 14 post SIV infection. All cells and staining reagents were kept on ice throughout staining procedure. Centrifugation steps were conducted at 4°C – 3500 X g. Whole blood (200 μL) was washed in Dulbecco’s phosphate buffered saline (dPBS) and stained for 30 min with UV blue Live dead assay (Invitrogen, Carlsbad, CA). Post live dead stain, whole blood was washed and then blocked using flow cytometry buffer (eBioscience, Waltham, MA). Cells were pelleted and surface epitopes were stained for 45 min with a cocktail containing brilliant stain buffer and fluorochrome-conjugated monoclonal antibodies against CD3-BV421, CD4-BV786, CD8-PeCy7, CD11b-BV605, CD14-EC, CD16-APCH7, and CD20-BV711. After surface epitope staining, cells were washed with flow cytometry buffer, pelleted and red blood cells were lysed a total of three times with red blood cell lysis buffer (Sigma Aldrich, St. Louis, MO). Lysed whole blood was washed in flow cytometry buffer, pelleted, and fixed using 1% paraformaldehyde in flow cytometry buffer. Cells were held overnight at 4°C before acquisition. All events were acquired using the BD Fortessa X450, and data were analyzed using BD FACSDiva v9.0 or FlowJo for Mac version 10.6 (BD Biosciences, Ashland, OR).

Complete blood counts were performed in the CLIA-certified Pathology labs of Nebraska Medicine. The lymphocyte percentage was determined as proportions of white blood cells. The lymphocyte percentage was multiplied by the white blood cell count to obtain lymphocytes per microliter, and further multiplied by the flow cytometric determination of the CD3^+CD4^+ and CD3^+CD8^+ proportions within the lymphocyte FSC/SSC gate on live cells to obtain the number of CD4^+ and CD8^+ T-cells, respectively, per microliter.
of blood. For the monocytes, the proportion of CD14 + CD16− cells within the FSC/SSC gate on live cells of the total live cells within this gate was reported.

Analysis of peripheral biomarkers
For analysis of analytes in peripheral blood, EDTA-anticoagulated plasma was collected at necropsy and sent to Myriad RBM (Austin, TX) for analysis using the Human v2.0 Multianalyte profile (MAP) immunoassay. The assay examined 85 total analytes, which are listed in Table S1. The 46 analytes that were detected in our macaques and the normal ranges determined by analysis of plasma from 39 healthy Rhesus macaques, are shown in Table 1. Although these MAPs are designed for human samples, Myriad RBM assays have been previously used for successful analysis of non-human primate inflammation and neurological disease (By-nes-Blake et al., 2012; Dietsch et al., 2015; Gautam et al., 2018; Kobayashi et al., 2013; Olsen et al., 2010; Shen et al., 2016). However, for analytes with all undetectable readings, these may either be due to lack of cross-reactivity or the absence of those molecules in the samples tested. All samples were stored at less than −75°C until tested. Samples were thawed at room temperature, vortexed, spun at 3700 × g for 5 min for clarification and transferred to a master microtiter plate. Using automated pipetting, an aliquot of each sample was added to individual microsphere multiplexes of the Human v2.0 MAP and blocker. This mixture was thoroughly mixed and incubated at room temperature for 1 h. Multiplexed cocktails of biotinylated reporter antibodies were added robotically and after thorough mixing, incubated for an additional hour at room temperature. Multiplexes were labeled using an excess of streptavidin-phycocerythrin solution, thoroughly mixed and incubated for 1 h at room temperature. The volume of each multiplexed reaction was reduced by vacuum filtration and washed 3 times. After the final wash, the volume was increased by addition of buffer for analysis using a Lumex instrument and the resulting data interpreted using proprietary software developed by Myriad RBM. For each multiplex, both calibrators and controls were included on each microtiter plate. Eight-point calibrators to form a standard curve were run in the first and last column of each plate and controls at three concentration levels were run in duplicate. Standard curve, control, and sample QC were performed to ensure proper assay performance. Study sample values for each of the analytes were determined using weighted and non-weighted curve fitting algorithms and 4 and 5 parameter logistics.

Analysis of monoamines and metabolites
Isolation of brain tissue was performed carefully in anoxic conditions to prevent oxidation of dopamine and enable its analysis by HPLC as described above. Tissue (~200 mg) from brain sections collected on ice was placed in ice-cold, pre-filtered HeGA. Samples were disrupted and homogenized using an ultrasonic homogenizer (Model 300VT, Biologics, Inc., Manassas, VA) at 80% power, with 2 s pulses over 15 s followed by 5 s off and repeated a total of six times. Homogenized tissues were aliquoted and stored at −80°C. For HPLC analysis, samples were thawed on wet ice, and then centrifuged for 4 min at 16,000 × g at 4°C. The supernatant was removed and stored at 4°C until sampled for analysis using HPLC coupled to electrochemical detection (no more than 12 h). From 3 to 10 μL samples were drawn once every 35 min using an autosampler (Shimadzu, Kyoto, Japan). Separation was achieved as previously described (Brodnik et al., 2017a, 2017b; Brodnik and Jaskiw, 2015), using a 100 × 3-mm reversed-phase C18 column with 3-μm particles (Phenomenex Luna C-18 (2), CA, USA) column. The mobile phase consisted of 12.5 mM citrate, 20 mM acetate, and 0.1 mM EDTA, with 5% (v/v) methanol adjusted to pH 6.0 with sodium hydroxide and 0–3.0 mM octyl sulfonic acid adjusted as a modifier. Dopamine (DA), serotonin (5-HT), and the metabolites 3,4-Dihydroxyphenylacetic acid (DOPAC), 5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) were quantified with a glassy carbon electrode maintained at a relative potential of 0.65 V to an Ag/AgCl reference electrode (Antec Decade Elite, Zoeterwoude, The Netherlands).

SIV cell-associated RNA quantification from frozen tissues
Total cell associated SIV RNA was quantified using RT-ddPCR using 100 ng of RNA, One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad, Hercules, CA) and same set of primers and probe used for SIV plasma viral load quantification; ddPCR was carried out on Bio-Rad QX200 AutoDG digital droplet PCR system as described previously (Cline et al., 2005). In brief, 22 μL of reaction mix was used for droplet generation using QX200 Droplet Generator. The 22 μL of reaction mix contains 5 μL of super mix, 2 μL of reverse transcriptase, 0.5 μL of 20 μM forward primer, 0.5 μL of 20 μM reverse primer, 0.25 μL of 20 μM probe, 1.0 μL of 300 mM DDT, 2.5 μL of Nuclease Free Water and the rest template RNA. The ddPCR plate with the emulsified samples was heat sealed and amplified in a C1000 Touch thermal cycler (Bio-Rad, Hercules, CA). The thermal cycling condition of the reaction was 48°C for 1 h, 95°C for 10 min, 45 cycles of 94°C for 30 s and
59°C for 1 min, 98°C for 10 min and hold at 12°C. After thermal cycling, ddPCR plates were transferred to the QX200 droplet reader (Bio-Rad, Hercules, CA) for droplet count and fluorescence measurement. Positive droplets with amplified products were separated from negative droplets without target amplicon by applying a fluorescence amplitude threshold and the absolute quantity of RNA per sample (copies/µL) was determined using QuantaSoft software (Bio-Rad, Hercules, CA).

Immunohistochemistry and RNAscope
Tissues were fixed in 10% neutral buffered formalin for 48 h, transferred to 70% ethanol, and processed for paraffin embedding. Five µm thick tissue slices were dehydrated at 60°C, deparaffinized and rehydrated in a series of xylene and graded ethanol (100%, 95%, 75%, 50%, dPBS). Slides were rinsed with dPBS and blocked for endogenous peroxidases using 3% H2O2 in methanol, slides were again rinsed in dPBS. Heat induced antigen retrieval was completed by submerging sections in 0.1 M sodium citrate, pH 6.39 for 30 min at room temperature. Sections were stained with the primary antibody, Iba-1 (ionized calcium binding adapter molecule 1, gene symbol A1f1; Fujifilm Wako Pure Chemical Corporation, Osaka, Japan) in blocking buffer (1:1000) and placed on a rotating platform at 4°C overnight. The following day, after washes in dPBS, secondary ImmPress – HRP Horse Anti-Rabbit IgG Polymer (Vector Laboratories, Burlingame, CA) was applied for 1 h at room temperature. Visualization was achieved utilizing Nova Red and counterstained with Hematoxylin QS (both from Vector Laboratories, Burlingame, CA).

In situ hybridization for SIV RNA was performed using RNAscope (Advanced Cell Diagnostics, Newark, CA) with probes targeting SIV (which targets SIV coding sequences of gag, pol, vif, vpx, vpr, nef, and tat). Target amplification and color development was done using the 2.5 HD RED Assay (Advanced Cell Diagnostics, Newark, CA) and sections counterstained with Hematoxylin QS following manufacturer’s protocol.

NanoString and quantitative real-time PCR (qRT-PCR)
Total RNA was extracted according to manufacturer’s instructions from 70 to 180 mg of the indicated brain regions, liver, and spleen using TRIzol (Life Technologies, Carlsbad, CA). RNA was further purified using the RNA Clean-Up protocol using theQiagen RNeasy Mini Kit (Qiagen, Germantown, MD). The nCounter NHP Immunology expression panel from NanoString was performed by UNMC Genomics Core using the nCounter digital analyzer 5s DNA RNA. The gene targets and their percent identity with M. mulatta are listed in Table S2. Selected transcripts were validated by qRT-PCR. For qRT-PCR, two µg of total RNA was reversely transcribed to a total volume of 100 µL cDNA. Sixteen µL RNA (125 ng/µL), 8 µL random primers (30 µg/µL) and 3 µL dNTPs (10 mM) (Invitrogen, CA), were incubated at 65°C for 10 min and 4°C for 5 min. Four µL 100 µM DTT, 8 µL 25 mM MgCl2, 8 µL 5X First Strand Buffer and 1 µL SUPERase.IRN (20 U/µL) (Invitrogen, Carlsbad, CA) were added and incubated at 42°C for 2 min and 4°C for 5 min. Lastly, 1 µL of Invitrogen SuperScript IV Reverse Transcriptase (200 U/µL) (Invitrogen, Carlsbad, CA) was added and the reaction was incubated at 25°C for 10 min, 42°C for 20 min, and 70°C for 15 min with a 4°C infinite hold. Total volume was brought up to 100 µL with RNase free water. Real-Time PCR was performed using the Step-One Plus real-time PCR machine. Each 20 µL reaction contained 1× TaqMan Gene Expression Master Mix (Applied Biosystems, CA), 5 µL cDNA template, and primer probe sets. Primer probe sets were purchased from Thermo Fisher Scientific (Waldham, MA): CXCL11 #Rh02621763_m1, OAZ1 #Rh02809570_gH, OAS2 #Rh02842591_m1, IRF1 #Rh00971962_m1, MX1 #Rh02842279_m1, ALAS1 #Rh02829381_m1. The TBP Primer Probe Set was synthesized by Eurogentec (Freemont, CA): TBP Forward: aaagaccattgcacttcgtg TBP Reverse: ggttcgctctcttatcc and TBP Probe: tcccaagcggtttgctgcag. The cycling profile used for PCR reactions was as follows: 2 min 50°C, 10 min at 95°C, followed by 40 cycles with 15 s at 95°C and 1 min at 60°C. For determination of relative expression, the Ct values of ALAS1, OAZ1 and TBP were averaged for housekeeping gene normalization.

QUANTIFICATION AND STATISTICAL ANALYSIS
If not otherwise mentioned, statistical analyses were performed using Graph Pad Prism 9.0. Prior to analyses, all assays were analyzed for normality and outliers were removed using Grubb’s test for outliers. Differences between viral loads and immune cell subsets in groups of SIV-infected animals treated with saline or deprenyl were analyzed using multiple T-tests or Mann-Whitney tests if data were non-parametric and correcting for multiple comparisons using the Holm-Sidak method. For peripheral biomarkers, to enable comparisons between analytes in which the mean of one group was below the limit of detection, analyte
values were set to the one-half of the limit of detection for the purpose of graphing and analysis. Analytes were determined to be undetectable if less than 5 of the 16 samples contained detectable analyte. Changes in peripheral biomarkers were analyzed using multiple T-tests (Mann-Whitney tests if data were non-parametric) and correcting for multiple comparisons using the Holm-Sidak method.

Concentrations of dopamine, serotonin, and metabolites were analyzed using an ordinary 2-way ANOVA, assessing the effects of deprenyl and SIV infection. For flow cytometry, Graph Pad Prism 9.0 software was used to carry out statistical comparisons and plot figures. Descriptive statistics were presented to summarize continuous variables. Wilcoxon rank sum tests were used to determine the statistically significant difference in continuous outcomes between groups for flow cytometry data. To analyze the gene expression data generated using the NanoString array, NanoString nSolver was used for background thresholding and normalization of gene counts prior to t-tests, with multiple testing correction by the Benjamini-Yekutieli method. The housekeeping genes used for all analyses were ALAS1, DDX50, ERCC3, HDAC3, OAZ1, PPIA, and TBP. Effects were considered significant if the p value was below 0.05.